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Abstract of the Dissertation
Transmembrane Domain Structure and Function in the Erythropoietin Receptor
by
Ian Christopher Brett
Doctor of Philosophy
in
Biochemistry and Structural Biology

Stony Brook University
2012

Activation of the erythropoietin receptor (EpoR) by the soluble cytokine erythropoietin (Epo) is
essential for the differentiation of erythrocyte progenitors and their development into red blood
cells. The single transmembrane (TM) helix of the EpoR mediates dimerization of the receptor in
the inactive state and is responsible for coupling ligand binding to activation of an intracellular
Janus kinase. Neither the structure of the inactive dimer nor the structural changes in the TM
region that occur upon ligand binding are known. This work presents the solution NMR
structures of peptides corresponding to the TM and juxtamembrane (JM) sequences that bridge
the extracellular and intracellular domains. The N-terminal end of the TM-JM peptides contains
the transition point between the last !-strand of the extracellular D2 domain of the receptor and
the TM "-helix. NMR measurements indicate that the TM helix extends to Pro225. This proline
allows Asp224 to fold back and form side chain hydrogen bonds to the backbone NH of Leu226.
Structural studies on the TM region of the EpoR alone reveal intermolecular contacts between
polar residues (Ser231, Ser238 and Thr242). At the intracellular TM-JM boundary, the defined
"-helical structure appears to break at Arg250-Arg251. However, Leu253-Lys256 exhibit
downfield carbonyl chemical shifts consistent with helical structure for the JM switch region. To
stabilize the TM-JM peptides in an active conformation, two approaches were undertaken. The
first approach was to substitute Leu223 with cysteine; full length L223C EpoR is constitutively
active. The second approach was to characterize the complex between the TM-JM dimer and the
TM domain of an EpoR-activating viral membrane protein, gp55-P. In both cases, the largest
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chemical shift changes were at the intracellular TM-JM boundary, particularly His249.
Mechanisms of receptor activation that unite biophysical and biochemical data are discussed.
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Chapter 1-Introduction
Cytokine Receptor Structure and Biology
The cytokine receptor family performs a wide variety of essential biological functions
including the growth and development of multiple cell types (e.g., blood cells) or regulation of
the immune system (1). Members of this family of receptors commonly feature at least one
cytokine receptor homology domain (CHD) composed of the fibronectin derived D1 and D2
domains; the D1 domain has 4 conserved cysteines and the D2 domain has a conserved WSXWS
motif. The receptors that have functional intracellular domains (ICD) share homology as well,
containing the conserved Janus kinase (Jak) binding sites Box 1 and Box 2. Each receptor shows
high conservation across species (2). They are subdivided into 5 subgroups based on sequence
homology, receptor structure, and type of functional oligomer (homo- or heterooligomer). Group
2 is the largest subgroup and has the most diverse extracellular domain (ECD), with a varying
number of fibronectin and immunoglobulin domains in addition to the CHD. This group contains
the gp130 common signaling chain receptor used by several of the Group 2 members. Group 3
also has a modified ECD containing an immunoglobulin domain in addition to the CHD; several
of its members also use gp130 as a common signaling chain. Groups 4 and 5 are also
heterocomplex receptors, but instead of using gp130 as the common signaling chain, either IL2#c or IL-3R!c are used.
Group 1 is made up of homodimeric receptors, including the receptor that is the focus of
this research, the erythropoietin (Epo) receptor. Other Group 1 members include receptors for
thrombopoietin (Tpo), growth hormone (GH) and prolactin (Prl) (Figure 1.1). Together, these
four receptors are structurally similar with the exception of the TpoR. It has a duplicated ECD
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(2x CHD), only one of which binds ligand, and a five-residue insert at the C-terminus of the
transmembrane (TM) domain. Each of these receptors uses Jak2 and STAT5 (signal transducer
and activator of transcription) for intracellular signaling.
The active form of Group 1 receptors is a dimer. The ligand is bound in a cleft between
the two halves of the receptor dimer ECD in an asymmetric fashion, using a high-affinity site on
one receptor monomer and a low-affinity site on the other (3). Ligand makes contact with several
residues from both the D1 and the D2 domains. A short flexible linker region between the two
domains allows changes in the relative position of the two domains in response to ligand. The
conserved WSXWS motif in the second fibronectin fold of the CHD is necessary for proper
receptor function and trafficking to the membrane. Solution nuclear magnetic resonance (NMR)
structures of the D2 domain of the GH receptor and the IL-6 receptor (4, 5) and crystal structures
of the GHR, PrlR and the EpoR extracellular domains (6-9) revealed that the conserved
tryptophan residues of the WSXWS motif interact with conserved arginine residues in the CHD,
likely stabilizing the structure of this domain. Mutagenesis of this motif performed in several
receptors to gain insight into the potential structural and functional roles of the WSXWS motif
(10, 11) usually resulted in decreased affinity for ligand. These results led researchers to
hypothesize that WSXWS was involved in ligand binding. However, a more definitive WSXWS
mutational study performed by Hilton et al. (12) determined that while the W232 and W235
residues had a very narrow mutational range (where functionality is preserved only if replaced by
Phe or Tyr), S233 and S236 functioned with a wider range of mutations. In addition, the EpoR
could still bind Epo when position A234 was mutated to almost any other residue. Despite the
fact that mutation generally decreased receptor activity, Epo binding assays indicated that even
mutant receptors that made it to the cell surface were capable of binding Epo and productive
%

signaling. This result is more consistent with the WSXWS motif performing a structural role in
folding of the Epo receptor. Indeed, when the crystal structure of the Epo receptor ECD with
ligand bound was solved, the WSXWS motif was located outside of the Epo binding site (8).

Figure 1.1 Group 1 cytokine receptor family members. Four members of the Group 1 cytokine
receptors share general structural homology with each having an extracellular cytokine
homology domain, a single transmembrane domain of varying length, and an ICD with a
variable number of tyrosines, capable of non-covalent binding to a Janus kinase. The TpoR has
two unique features: a duplicated extracellular domain and a five-residue insert (R/KWQFP)
that modulates receptor activity. Epo:erythropoietin, Tpo:thrombopoietin, Prl:prolactin,
GH:growth hormone

&

Figure 1.2 Group 1 cytokine receptor family member TMD sequences, human and mouse. The
region including and around the TMD of the Group 1 receptor family members reveals
interesting features. Beginning with the conserved WSXWS motif, each member has an acidic
extracellular juxtamembrane domain of variable length, a hydrophobic TMD that shows
interspecies conservation, an intracellular switch region with basic residues and a proline-rich
Box 1 region that interacts with the Janus kinase. Conserved prolines are highlighted.
Epo:erythropoietin, Tpo:thrombopoietin, Prl:prolactin, GH:growth hormone

The TMD, in contrast, does not share sequence conservation across Group 1 cytokine
receptor members, though sequence conservation of each receptor between species is generally
seen (2). Alignments of the TMD sequences from Group 1 receptors produce no useful
comparisons (Figure 1.2), and though these receptors are thought to function as dimers, no clear
TM dimerization motifs are seen. Given the conflicting reports about the role of the TMD in
receptor dimerization of this subgroup of receptors (13-17), this is not surprising. For instance,
studies show that both wild type GHR and chimeric GHR with the TMD replaced with the lowdensity lipoprotein receptor (LDLR) TMD co-precipitate with a co-expressed, intracellular
domain (ICD) truncated GHR mutant (13). This result not only indicates that the TMD is not
necessary for dimerization of the GHR, but that the ECD is required. This observation is in
contrast to experimental results from the Epo receptor. When EpoR-PrlR chimeras are coexpressed in cells with full-length WT Epo receptor, receptor co-patching only occurs when the
EpoR TMD is present (14). A related study of truncated Prl receptors (ECD-TM or ICD-TM)
indicated that when co-expressed in cells the ECD-TM inhibited signaling, while the ICD-TM
construct augmented signaling (16). These results suggest that the TMD mediates PrlR
'

interaction. Using the TOXCAT expression-reporter system (18), further studies of the Epo and
GH receptors indicate that the propensity for TM self-association is four times greater for the
EpoR TMD than the GHR TMD (19).
While the EpoR and TpoR TMDs are leucine-rich, the GHR and PrlR TMDs are not. The
presence of polar residues in the TMD is interesting. Studies show that when present they
typically perform a critical function, such as mediate interhelical interaction (20). While the
GHR is rich in aromatic residues, the other members are not. It is clear that the sequence of the
TMD plays an important part in the function of each receptor, but if dimerization is mediated by
the TMD a single dimerization motif that governs all of these receptors is unlikely to be found.
The ICDs of these receptors are arguably the most important and least understood part of
the molecule. The ICD is responsible for both binding the tyrosine kinase molecule and
harboring the tyrosine residues that, when phosphorylated, allow binding of adapter proteins for
several downstream effector pathways. Each receptor has a variable length tail with a variable
number of tyrosines, only some of which are essential for basic receptor function (21), the rest of
which often function as docking sites for accessory pathway proteins (22). An important
conserved region of the ICD is the Box 1 motif (Figure 1.2), necessary for binding the Janus
kinase tyrosine kinase (23, 24). A second important Jak binding site is the smaller Box 2 motif
(24-26).
Other interesting observations can be made regarding the receptor sequence, especially
surrounding the TMD. First, the extracellular juxtamembrane region, like the TMD, is not highly
conserved, but is certainly important as it mediates the transition between the !-sheet rich ECD
and the "-helical TMD. It generally contains a number of acidic residues, the function of which,
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if any, is unknown. In contrast the “switch” region, located in the membrane proximal
intracellular juxtamembrane region, contains a number of basic residues. While these may be
part of the “positive-inside” rule (27, 28), in at least the TpoR these basic residues have a defined
role as part of a receptor-recycling motif (29).
Cytokine Receptors and Disease
The diverse array of biological processes regulated by the cytokine receptors make them
targets for disease-causing mutation or other modulation resulting in pathology. Mutations can
cause gain-of-function or loss-of-function, leading to physiological states that may be
characterized as being within normal limits or pathologic, depending on severity. Interestingly,
each receptor does not seem to have an equal chance of acquiring a pathologic mutation. For
instance, the TpoR has several described mutations, but the EpoR does not. This may reflect a
difference in the structural requirements for signaling, a difference in tolerance of variability in
the ultimate physiological response, or differences in importance of the pathway either overall or
at different stages of organism development.
The most common mutation associated with increased cytokine receptor function occurs
in the associated Janus kinase, in EpoR/TpoR, Jak2 (JAKV617F) (30). It is unknown exactly
how this mutation causes a gain of function, but the mutation occurs in the pseudokinase region
of the kinase, which is thought to regulate C-terminal kinase activity (31). However, mutation in
the receptors can modulate activity as well, presumably by inducing structural changes in the
receptor. A mutation in the ECD of the EpoR (R129C) causes constitutive receptor activation in
mice (32). Point mutations in the TpoR TMD (S505N), the EC-JM region (T487A), or the IC-JM
region (W515K/L) cause constitutive TpoR activation (33-35). Alternatively, deletions in the
intracellular C-terminus of the TpoR resulting in a truncated receptor can cause
)

thrombocytopenia (36), while organisms possessing an EpoR with a truncated intracellular Cterminus exhibit polycythemia (22).
The Friend spleen focus forming virus infects mice and causes erythroleukemia (37). It
possesses a TM protein, gp55-P, which interacts with the TMD of the EpoR (38). This
interaction is specific to the murine EpoR TMD, as it does not activate the human receptor. This
specificity has been traced to the S238 residue in the murine EpoR, which is a leucine in the
human receptor (39). Mutation of this residue to serine in the human TM sequence allows the
EpoR to be activated by gp55-P (39). Expressed gp55-P349-409 is used here in conjunction with
expressed muEpoR218-268 to probe possible effects on the EpoR TM structure.
Erythropoietin and Erythrocyte Development
Erythrocytes are the cells responsible for oxygen transport. In adult mammals these cells
are produced in the bone marrow in a carefully regulated cascade involving several organs.
Decreased oxygen delivery is sensed by cells in the kidney (40), which triggers a release of
erythropoietin (Epo). Epo travels to the bone marrow where pluripotent stem cells (PSCs) give
rise to all hematopoietic cell precursors. The particular precursor for erythrocytes, the
erythrocyte blast forming unit (BFUe), is differentiated from PSCs by a combination of stem cell
factor, IL-3, Tpo, and GM-CSF (granulocyte macrophage colony stimulating factor), but it is
Epo that provides the definitive signal to begin differentiation to erythrocytes (41, 42).
The protein hormone Epo is a 30.4 kDa member of the four helix bundle cytokine family
(43). Secreted by specialized cells in the outer cortex of the kidney it travels through the blood
until it encounters the ligand-binding domain of the membrane-embedded Epo receptor on the
cell surface of hematopoietic stem cells (HSCs) where it binds with high affinity. The Epo
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receptor is a homodimer formed from two 66 kDa monomers which have sequence and structural
homology to other members of the hematopoietin cytokine receptor subfamily (Figures 1.1, 1.2).
The ECD portion of the Epo receptor has been well studied. Several crystal structures of the
ECD exist at varying resolutions. In the absence (PDB ID:1ERN) (9) and presence of either the
native ligand (PDB ID:1EER/1CN4) (8) or an Epo stimulatory peptide (PDB ID:1EBP) (44), the
ECD is a dimer. The crystal structure of the Epo-bound ECD (PDB ID:1CN4) (8) confirms that
the ratio of receptor to hormone in the active complex is 2:1, with the Epo molecule binding to
the two halves of the ECD in an asymmetric fashion. Cellular studies confirm that the active
state of the receptor is in fact a dimer (45).
The next well-defined domain is the hydrophobic TMD that consists of roughly 25
mostly hydrophobic amino acids. It allows tethering of the receptor in the membrane bilayer of
the HSC and provides a route of communication between the EC and IC domains. The role of the
ICD is perhaps the most poorly understood. This portion of the receptor has two conserved
features important for proper receptor function, the Box 1 and Box 2 motifs that are important
for Jak2 binding. There are 8 tyrosine residues present that are phosphorylated by Jak2 to allow
binding of effector proteins, such as signal transducers and activators of transcription (STATs).
These tyrosine residues are non-equivalent, Y343 is the only one shown to be absolutely
necessary for activation (21). Most of the others can signal in a positive or negative regulatory
fashion (22).
Receptor processing is an important part of the “life cycle” of the EpoR. After protein
translation the receptor pre-associates with Jak2 in the endoplasmic reticulum (ER); most of the
pool of Epo receptor does not leave the ER without Jak2 bound (46). This finding may be
consistent with other members of the cytokine receptor family, as the TpoR behaves similarly
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(47). After release from the ER the Epo receptor moves to the Golgi where oligosaccharide is
added to the Jak2-bound fraction of the EpoR (46). This differentiates mature receptor (endo-H
resistant oligosaccharide, 66 kDa) from the less mature form (endo-H sensitive, 64 kDa). Once
the receptor is activated termination of signaling occurs by receptor internalization mediated by
ubiquitination of cytoplasmic lysine residues, particularly K256, which mediates activationinduced internalization, and K428, which directs internalized receptor to the lysosome for
degradation (48). These ubiquitination reactions are dependent on the activity of Jak2, and
receptor that is not degraded by the lysosome can be degraded by the proteasome (49).
Mechanism of Receptor Activation
The activation mechanism of the EpoR is an area of active research. Previously it was
thought that the receptor existed as a monomer, and two receptor monomers came together in the
presence of ligand (50). More recently, it has become accepted that the Epo receptor exists as a
pre-formed dimer (dimer in the absence of ligand) (51). The existence of a pre-formed, inactive
dimer suggests that the receptor dimer resides in some low-energy conformation in the absence
of ligand. Then, when ligand binds to the ECD, the global receptor structure is perturbed in a
way that allows activation of the ICD-bound Jak2 molecules. This position is the result of two
experimental studies. The first is that the crystal structure of the unliganded ECD is a dimer (9).
The second comes from Förster resonance energy transfer (FRET) experiments using other
receptors from this family. FRET studies using the GHR (52) indicate that these receptors form
dimers in the absence of ligand. Furthermore, heterodimeric receptors associate as pre-formed
dimers; as gp130 and LIF-R can be co-precipitated in the absence of ligand (53). Interestingly,
similar FRET studies on the EGF receptor, a receptor tyrosine kinase (RTK) single TMD
receptor shows that these receptors are also pre-formed dimers (54). However, this is
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controversial as other reports have found inactive monomers (55), heterodimers (56), and
activated higher-order oligomers (57). The importance of pre-association of receptor monomers
is not known, but in theory having a pre-formed receptor complex awaiting only ligand should
ultimately decrease activation latency. The following sections discuss receptor dimerization in
the context of each domain of the receptor.
Extracellular Domain
The position or location of cytokine receptor monomer association is a point of
contention. Studies of the ECD crystal structure of the ECD in the absence of Epo (PDB
ID:1ERN) support the idea that the ECD mediates receptor dimerization (9). Several residues in
the interface between the two halves of the ECD dimer are proposed to form near-symmetric
interactions. When compared with the crystal structure of an non-Epo agonist-bound ECD (PDB
ID:1EBP) (44) the domain movements involve a 13° rotation of D2 towards D1 and a change of
the relative positions of the D2 domain C-termini from 73 Å to 39 Å (Figure 1.3). The Epobound structure shows similar domain movements (8). The relative positions of the two D1
domains in the ligand-bound structures are different, as the inter-D1 domain angle is 120° in the
Epo-bound structure and 180° in the EMP-bound structure. This difference is likely due to more
Epo-ECD contacts than the EMP-ECD structure, as Epo is a larger ligand. This observation
suggests that the differences in biological activity of the two ligands (Epo > EMP) (58) originate
from structural differences between ECD-ligand complexes.
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Figure 1.3 EpoR ECD intra- and inter-domain motion upon ligand binding. Crystal structures
of the EpoR ECD in the absence (left, PDB ID:1ERN) and presence of Epo (right, PDB
ID:1CN4) demonstrate intra-ECD domain motion (D1-D2) and inter-ECD motion upon ligand
binding. Inter-ECD motion demonstrates that the D2 domains rotate to be in close proximity. D1
domains are highlighted with dark ellipses, D2 domains are highlighted with light ellipses.
Points of inter-ECD contact are seen in both the unbound and Epo-bound structures. In
the ligand-unbound structure, residues that normally interact with the ligand form contacts in the
buried surface between the two ECD monomers (Phe93, Phe205, Leu33, Pro140, Met150).
When either ligand is added the D2 domains move closer together, and residues in the D2
domain move within contact distance. Hydrogen bonds are formed between Glu134 and Ser135
on opposite D2 domains to stabilize the dimer (8). In contrast, a more extensive interface exists
between the D2 domains of the GH receptor, which may contribute more to dimerization (45).
The result of studying crystal structures of the ECD without and with ligand suggests that
there must be a significant rotation of the ECDs relative to each other as well as a change in D1$$

D2 domain angle in order to activate (8). This hypothesis agrees with the computational studies
on the GH receptor that describe a 45° rotation of the ECD upon GH binding (59). Pang and
Zhou (60) also propose a similar rotation model based upon the crystal structures of the ECDs of
the EpoR, PrlR, and GHR but with a twist. In their model each half of the ECD dimer performs a
rotation and scissor motion, where they rotate toward each other about an axis perpendicular to
the membrane, then the D2 domains pivot to bring together the C-terminal ends of the ECD (60).
Consequently, the ICDs are brought closer together, allowing activation of Jak2.
Transmembrane Domain
Concurrent with the flurry of research on the Epo receptor ECD crystal structures,
membrane protein groups investigated the role of the TMD on the function and activity of the
Epo receptor. Gurezka et al. (61) used the TOXCAT assay to assess the propensity of the Epo
receptor TMD to oligomerize and found that the self-association was the strongest of all TMDs
studied that contained the leucine heptad repeat. This work led to a proposed dimerizing motif
for the TMD of the Epo receptor, the leucine heptad repeat (LLxxLLx- LLxxLLxLL). This
heptad repeat is a reference to the Leu zipper family of helical proteins that form sequence driven
homodimers (62, 63). Originally found to exist in DNA-binding proteins, the dimerization of
these proteins is driven by the interaction of Leu sidechains across the homodimer and this
consensus sequence is found in a variety of TM and non-TM proteins. Subsequent experiments
demonstrated that perturbation of this sequence by replacing Leu240 and Leu241 with Gly-Pro
abrogated receptor activation as measured by colony formation, even when coupled with the
activating R129C mutation (19). The leucine zipper dimerization motif in the EpoR was
investigated further by examining the effect of asparagine mutagenesis on TMD oligomerization
(64). L241N was found to increase TM oligomerization as measured by the TOXCAT assay.
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This result led to a refinement of the Leu heptad repeat consensus to include serine residues in
the interface (SxxLxxx-SxxLXxxxA).
Further work demonstrated a difference in the strength of association of the mouse and
human Epo receptor TMDs. Ebie and Fleming (65) conducted analytical ultracentrifugation
(AUC) on fusions of either the human or murine Epo receptor TMDs with staphylococcal
nuclease. These studies demonstrated the intrinsic propensity of the Epo receptor TMD to
dimerize in detergent micelles and found a difference in the free energy of association between
the murine and human sequences of 1.3 kcal mol-1 and 0.4 kcal mol-1, respectively. Sequence
alignments of the two receptors (Figure 1.4) point toward 3 differences between the two
sequences that may be responsible for the change in association energy. These three changes
surround Ser238(mouse)/Leu239(human), indicating the importance of this region to the murine
Epo TM association. The fact that the murine TMD sequence dimerizes more strongly is
hypothesized to be due to the mouse’s higher turnover rate for erythrocytes (65) and implies that
the basal rate of signaling activity is linked to the strength of the TM dimer. These results
indicate that the oligomerization of the TMD is not indiscriminant clustering, but rather there
exists a sequence-dependent association. These findings are consistent with sequence-specific
oligomerization seen in other TM protein systems, such as glycophorin A (66), BNIP3 (67), and
integrin TM helices (68).
Intracellular Domain
Research on the ICD sequence has identified several regions critical for Epo receptor
function. The Box 1 (69) and Box 2 (70) regions are critical for binding Jak2, and the eight
tyrosine residues are necessary for activation of downstream signaling pathways (21, 71). More
detailed study of the residues connecting the C-terminus of the TMD and the Box 1 region have
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identified 3 critical residues: Leu253, Ile257, and Trp258 (72). These residues are important for
receptor activity, as mutation to alanine abrogates receptor function. Furthermore, their proper
orientation is critical as insertion of 1 or 2 alanine residues between the TMD and Leu253
destroys receptor function. Interestingly, addition of three alanines (~1 helix turn) recovers
activity, providing a hint that the region connecting the TMD and these “switch” residues is
helical. Together, these data are suggestive of a rigid structural link between the TMD and the
ICD.
Discordance of Data from Different Regions
Data collected from the study of the ECD suggest an inactive receptor model in which the
TM domains are monomeric (9), while EpoR TMD studies in detergent (65) and in bacterial
membranes (64) indicate that the EpoR TMD has a propensity to associate in a sequence-specific
manner. The conflict between ECD dimerization data and TM dimerization data sets up a major
question in cytokine receptor biology, “What is (are) the point(s) of receptor self-association?”
This question cannot be answered by merely studying pieces of the receptor; it can only
determine the relative strengths of self-association. Therefore, Constantinescu et al. (73)
examined dimerization of the full-length receptor in cellular membranes. Using chimeras of the
Epo and Prl receptors, it was determined that the TMD was both necessary and sufficient to
cause receptor copatching in BOSC (human embryonic kidney) cells (73). Further studies were
conducted to determine whether the orientation of the TMD is important in receptor activation.
Cysteine mutagenesis studies on the TMD in the background of the full-length receptor in BaF3
cells indicated that when mutated, several residues in the N-terminus could either increase basal
levels (Leu223, Leu226/Ile227) or severely decrease maximal levels of signaling (Asp224,
Pro225) (74, 75). Furthermore, experiments studying Put3 coiled-coil-EpoR TMD fusions
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demonstrated a dependence of activity on the rotational orientation of the TMD (76).
Collectively, these results show that the TMD is critical for Epo receptor dimerization, and that
receptor activity is dependent upon TMD orientation.
Complementing the cysteine mutagenesis studies of full-length EpoR is a report of
asparagine mutagenesis of the EpoR TMD in cells (77), again correlating mutation with native
function. This is an extension of the Ruan et al. (64) study that used asparagine mutagenesis in
conjunction with the TOXCAT assay (18) to argue that the TM dimer interface of murine EpoR
is mediated by a serine-leucine zipper. In Ruan et al. (64), L241N exhibited the strongest
TOXCAT signal, indicating a strong dimer. However, in the background of the full-length EpoR
in cells, the results were slightly different with L241N and A245N being hypersensitive to Epo
(77). Interestingly, T242N responded at a lower level than WT to Epo, a result that was
mimicked by T242Q as well. Oddly, similar to A245N, T242A demonstrated a hypersensitivity
to Epo. The authors correlate the biological responses to TMD dimer models produced by
molecular dynamics, which show that the Epo-hypersensitive mutants (T242A, A245N) have a
smaller interhelical distance and packing volume than less active receptor mutants (T242N, Q)
(77). Interestingly, different species utilize threonine or alanine at position 242 of the EpoR
(Figure 1.4, (77)), but the reason for the difference is unclear. The AUC results mentioned above
indicate that the three residue difference between the mouse and human sequences surrounding
Ser238(mouse)/Leu239(human) indicate the importance of sequence specificity in TM
association. Together, these results indicate that the role of the peptide sequence in TM
dimerization is likely more complicated than a simple change in strength of TM association.
They also hint that changes in the interhelical distance may be integral to the activation
mechanism of the EpoR.
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Figure 1.4 Epo receptor TM region multiple species alignment. Epo receptor protein sequences
of the TM and surrounding region from 11 species show a high degree of conservation.
Highlighted are residues in the middle of the TMD where the human sequence is different from
the mouse (and others). Also indicated (orange) are the L-IW residues of the “switch” region
that are shown to be important for receptor function. S238 in the mouse TMD is in red text.
Sequence numbering provided is based on the human sequence minus the signal peptide.
Putting all of these data in context is difficult. Given that multiple experiments show that
the full-length Epo receptor is dimeric at the cell surface in the absence of ligand it seems
reasonable that a pre-formed dimer exists. Yet the activation mechanisms proposed to date by
study of the receptor piecewise are unsatisfying, as a single mechanism is not able to account for
all of the biochemical and biophysical data. Studies of the ECD structure propose mechanisms of
activation based upon data from what, in a functional sense, corresponds to only a third of the
total receptor. Many of the TMD studies suffer because they are performed on severely truncated
receptor TMDs. Also, conclusions from low-resolution TM association experiments are (perhaps
erroneously) interpreted as being solely the result of studying TM dimers instead of being
properly attributed to “oligomers of unknown constitution” (e.g., TOXCAT assay results). The
studies herein pick up where others leave off, studying the full TM sequence, at a sub-nanometer
level of resolution, to determine the structure of the TMD and surrounding regions of the Epo
receptor. From these studies, mechanisms of receptor function are proposed that are consistent
with these and other data from the literature.
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Strategy for Structure-Function Studies on the EpoR
Because the biochemical and biophysical evidence suggests that the TMD plays an
integral role in the function of the EpoR, we decided to undertake 3D high-resolution structural
studies of TMD-containing peptides in order to correlate structure and function. By starting with
small constructs containing only the TMD we can initially capture the relevant TM structure and
points of interaction between the receptor TM monomers. Then, studying longer constructs by
adding portions of the receptor sequence gives us the ability to examine how changes in TMD
structure are translated to the intracellular portions of the receptor.
This proposal assumes that the inactive and the active states can be “trapped,” and that
there will be some structural change that can be assessed by NMR. We assume that the WT
peptide sequence approximates the “inactive state.” We subsequently show using cysteine
mutants that this assumption is correct. Comparisons between the inactive TMD structure and the
active structures are accomplished in two ways. Because there are no clinically relevant
mutations in the EpoR as in the TpoR (W515K/S505N/T487A), we rely on two types of
activating mechanisms to approximate the active state, constitutive activity and allosteric
modulation. The first involves the identification of a constitutively active mutant (L223C) from
cysteine mutagenesis studies performed separately by two laboratories (74, 75). The second
involves a viral receptor activating protein, gp55-P, from the spleen focus forming virus (SFFV)
(38). This TM protein associates specifically with the TMD of the murine Epo receptor (39, 78),
causing activation and cell proliferation that supports viral replication.
Starting with constructs containing the smallest independently folded domain, the TMD
(muEpoR220-248), structural studies were conducted to determine the structure of the wild type
murine Epo receptor TM dimer. I found that the structure is a symmetric dimer, with
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dimerization mediated by intermolecular hydrogen bonds formed between the sidechains of polar
TM residues. My NMR studies of longer constructs that include the Box 1 region show a similar
structure. In addition, I determined that residue His249 is a marker of the active state, and thus
His249 is implicated in the activation mechanism.
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Chapter 2-Material and Methods
Cloning, Expression and Purification
Two fusion protein constructs were prepared using polymerase chain reaction in order to
clone portions of the murine Epo receptor sequence into the ligation-independent cloning HisMBP vector (kindly supplied by Dr. Tim Cross, NHMFL, Tallahassee, FL). The two TMDcontaining constructs correspond to residues 220-248 (muEpoR220-248) or 218-268 (muEpoR218268)

of the murine EpoR. The correct sequence was verified by DNA sequencing. Vectors

containing the correct fusion were transformed into chemically-induced competent Escherichia
coli BL21(DE3) cells. Expression of the fusion proteins was accomplished in M9 medium
without isotopic labels or M9 medium containing either 1 g/L 15N-ammonium chloride or 1 g/L
15

N-ammonium chloride and 3.6 g/L U-13C-glucose (Cambridge Isotope Laboratories, Andover

MA). A single colony from an isolation streak on a Luria-Bertani agar plate (100 ug/mL
ampicillin) was expanded overnight in 25 mL Luria-Bertani broth containing 100 ug/mL
ampicillin in a shaking incubator at 37 ˚C. These cells were pelleted by centrifugation at 3,300 x
g for 20 minutes and then washed with 5 mL sterile M9 medium (79) and centrifuged again at
3,300 x g for 20 minutes. The resulting cell pellet was resuspended into 10 mL of M9 medium
and the entire volume was used to inoculate 1 L of the appropriate M9 medium (as above). These
cells were grown with shaking (200 rpm) at 37 ˚C until the OD600 reached 0.5-0.6 (~6 hours) at
which point the temperature was reduced to 23 ˚C and the culture was induced by adding
isopropyl "-D-1-thiogalactopyranoside (IPTG) to a final concentration of 0.4 mM. The culture
was allowed to continue incubating at 23 ˚C for 16-20 hours with shaking at 200 rpm. Cells were
collected by centrifugation and cell pellets were resuspended in 10 mL of ‘binding buffer’ (50
mM Tris, pH 7.9, 500 mM NaCl, 5 mM imidazole) and frozen at -20 ˚C until future use. These
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frozen cell aliquots were thawed and then the cells were lysed using a French press. Cell lysates
were clarified by centrifugation at 25,000 x g for 25 minutes at 4 ˚C. 200 mg octyl-!-Dglucoside ("-OG) was added to the supernatant and dissolved by nutation at 23 ˚C, ~5 minutes.
This mixture was then loaded onto a 10 mL Ni+/NTA column equilibrated with 20 mL binding
buffer (as above). Binding was accomplished by nutating the column for 2-4 hours at 4 ˚C. The
column was then allowed to flow through and washed with 16 times the column volume with
‘wash buffer’ (50 mM Tris, pH 7.9, 500 mM NaCl, 20 mM imidazole). The protein was then
eluted in 1 mL fractions with ‘elution buffer’ (50 mM Tris, pH 7.9, 500 mM NaCl, 500 mM
imidazole) until the A280 dropped to 0.05. Fractions above 0.05 were pooled (typically ~50 ml)
and n-dodecyl-!-D-maltoside (DDM) was added to a final concentration of 1.7 mM, which is
10x the critical micelle concentration (CMC). The yields of the fusion proteins were typically
about 100-120 mg/L.
To cleave the fusion tag (His-MBP) from the protein of interest, Tobacco Etch Virus
(TEV) protease was used. His-tagged TEV protease (His-TEV) was produced in-house, using
BL21(DE3) cells expressing His-TEV grown in Luria-Bertani broth and induced with 0.4 mM
IPTG. Purification of His-TEV proceeded in a manner similar to the TM containing the TM
fusion proteins described above, with the exception that no detergent was added to the cleared
cell lysate before incubating on the Ni+/NTA column. After elution, fractions with an OD280
higher than 0.05 were combined and sterile glycerol was added to 50% of the final volume (v:v).
Then dithiothrietol (DTT) was added to 5 mM final concentration and ethylenediamine
tetraacetic acid (EDTA) was added to 1 mM final concentration. Typical yields of TEV were 1722 mg/L. The fusion protein was combined with His-TEV in a 1:1 (v:v) ratio and the mixture
was nutated at 23 ˚C for 36 hours. Cleavage was confirmed by SDS-PAGE. To separate the TM%-

domain containing muEpoR220-248 or muEpoR218-268 from the His-MBP fusion tag, the His-TEV,
and any uncleaved fusion protein, the entire mixture was precipitated by addition of
trichloroacetic acid to a final concentration of 6%. The chalky white precipitate was collected by
centrifugation (3,300 x g, 20 minutes) and washed twice with 10 mL distilled deionized water.
The washed pellet was lyophilized for 16 hours and then the hydrophobic peptide content was
extracted by nutating for 2 hours at 23 ˚C with 9 mL of methanol:chloroform (90:10, v:v). After
two hours, the supernatant was removed by syringe and then filtered through a 0.22 µm PTFE
syringe filter. Estimations of the final protein yield were made based on the A280 (muEpoR218-268)
or A230 (for the muEpoR220-248 peptide), the molar extinction coefficient and Beer’s Law
(A=$ℓc, where $ is the molar absorption coefficient,ℓ is the pathlength and c is the
concentration), according to the method described by Aitken and Learmonth (80).
NMR Sample Preparation
The organic extract containing the peptide of interest was used for reconstitution based
on the protocol of Sulistijo and MacKenzie (81). Briefly, the appropriate amount of peptide (for
a particular final concentration in ~300 uL NMR sample, usually 1 mM) was aliquotted into a
separate glass vial and evaporated under dry argon or nitrogen gas to approximately 2 mL. 10 mg
d38-dodecylphosphocholine (DPC) was dissolved into this solution, and then water was added
dropwise until the solution, when agitated, produced large bubbles that did not immediately
dissipate. The sample was immediately frozen in a liquid nitrogen bath and then lyophilized in a
low pressure (~10 mTor) and low temperature (-95 ˚C) lyophilizer. To maintain the sample in a
frozen state, the entire lyophilization jar was placed in a Styrofoam container filled with ice.
Lyophilization typically took place over a 16-hour period. The dried sample was rehydrated in 1
mL 10 mM sodium phosphate, pH 7.0, using sonication to dissolve any precipitates. The sample
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was then dialyzed (1,000 Da MWCO) against 3 changes of 2 L 10 mM sodium phosphate, pH
7.0 to remove any residual glycerol or imidazole carried over from the TEV cleavage or TCA
precipitation steps.
The sample was then concentrated to ~250 uL in a 4 mL Millipore ultra 3 kDa MWCO
spin column (centrifuge speed, 3,000 x g for variable time). 30 uL of D2O was added for the
solvent lock along with 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) to 0.2 mM for an
internal reference.
Alternatively, a detergent exchange step is incorporated into the protocol. A nonnegligible amount of DDM can be carried over from the elution of fusion protein through the
TEV cleavage/TCA precipitation steps. While it does not seem to change the spectral data, the
presence of residual amounts of DDM can adversely impact the collection of certain NMR
datasets (e.g., NOESY-13C-HSQC). A protocol was developed to do an anion column detergent
exchange for Epo receptor TM containing peptides, based on a method described elsewhere (82).
Detergent Exchange
After reconstitution the sample was dialyzed into 20 mM Tris, pH 8.5 to exchange it into
a buffer that made the Epo receptor TMD negatively charged for anion exchange (and
simultaneously remove residual glycerol and imidazole). Two buffers were prepared, START
buffer (20 mM Tris, pH 8.5, 2x CMC d38-DPC) and ELUTE buffer (20 mM Tris, pH 8.5, 1 M
NaCl, 2x CMC d38-DPC). All buffers were degassed under vacuum for at least 20 minutes
before the addition of detergent. A 1 mL GE healthcare Q FF anion exchange column was
warmed to room temperature and equilibrated as per the manufacturer’s instructions (wash with
5 mL START buffer, 5 mL ELUTE buffer, then 5 mL START buffer). The sample was clarified
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by centrifugation (30 minutes at 20,000 x g) and loaded onto the column. The column was
washed with 10 column volumes of START buffer, collecting 1 mL fractions for gel analysis,
then eluted with 10 column volumes of ELUTE buffer. All fractions were saved for SDS-PAGE
analysis. The construct usually eluted in the first 5 fractions. These fractions are combined and
dialyzed against 10 mM sodium phosphate, pH 7.0 in order to exchange the sample into a more
“NMR friendly” buffer, then concentrated to ~270 uL using a 4 mL Millipore ultra 3 kDa
MWCO spin column (centrifuge speed, 3,000 x g for variable time). 30 uL D2O was added to the
sample and then it was loaded into a D2O susceptibility-matched Shigemi tube for NMR studies.
Analytical Ultracentrifugation
Sedimentation equilibrium experiments were performed on a Beckman XL-I analytical
ultracentrifuge at 25 °C. Samples for AUC were prepared in a manner similar to solution NMR
samples, co-dissolving peptide and detergent in organic solvent followed by lyophilization and
rehydration. The rehydration solution (50 mM Tris-HCl, 0.1 M NaCl pH 7.5, and 15 mM DPC)
was density matched to account for the buoyancy of DPC micelles by adding 52.5% D2O (83)
upon rehydration. Absorbance (A280) data points were collected in radial increments of 0.001 cm.
Three different peptide concentrations (~60 µM, 70 µM and 180 µM) and two different speeds
(40,000 rpm and 48,000 rpm) were used to ensure data quality. UltraScan II version 9.9 data
analysis software (developed by B. Demeler, http://www.ultrascan.uthscsa.edu/) was used to
process and analyze the data. Global curve fitting was accomplished using non-linear leastsquares analysis.
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NMR Experiments
Experiments were conducted on 3 different Bruker spectrometers; a 700 MHz equipped
with a TXI probe, a 700 MHz equipped with a TCI cryoprobe, and an 800 MHz equipped with a
TCI cryoprobe. To assign resonances to backbone atoms the following experiments were run:
1

H-15N-HSQC, HNCO, HNCACB, CBCACONH. For resonance assignment to sidechain atoms,

HBHACONH, HCCCONH, CCCONH experiments were run. Through space NOESY
experiments conducted to determine inter-residue distances were the 1H-15N NOESY-HSQC and
1

H-13C NOESY-HSQC experiments. To examine intermonomer contacts, two different

experiments were used. First, the X-filtered, edited NOESY experiment (84) was run using the
1:1 U-13C, U-15N:Unlabeled EpoR sample in 100% D2O (150 ms mixing). Second, the CNNOESY experiment (85) was run using a fully 13C, 15N labeled sample in 10 mM sodium
phosphate, pH 7.0, 200 mM DPC, 10% D2O (v:v).
Multidimensional experiments in solution NMR spectroscopy rely on two things,
application of radiofrequency pulses of a defined length, power, and frequency and application
of delays of a defined length of time. The radiofrequency pulses put energy into specific nuclei
in the molecule and the delays allow that energy to evolve or dephase according to the particular
set of nuclei that are being manipulated.
The values and particular combinations and precise application of these parameters are
what defines a “pulse sequence,” which is the computer code that controls the spectrometer’s
running of the experiment and allows magnetization transfer through nuclei in the molecule of
interest. These parameters are set in the acquisition parameters window of the NMR software.
Pulse sequence nomenclature for 3D experiments generally contains the names of atoms
involved in the experiment (HNCO = amide proton/nitrogen, carbonyl carbon). The
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magnetization transfer schemes presented in the figures below show how these multidimensional
experiments are conducted. Atoms that are circled represent atoms through which magnetization
is both transferred and evolve, that is, the frequency of the chemical shift of this atom is recorded
experimentally. Bonds through which magnetization is transferred are colored red. Multiple bond
transfers without chemical shift labeling of intervening atoms are represented by both colored
bonds and indicated by curved red arrows. For experiments that begin with an INEPT transfer
from proton to carbon to enhance carbon magnetization, such as CBCACONH, the proton
resonances are indicated in red and the bonds between the proton and carbon atoms indicated in
red, demonstrating that the proton resonance and the J-coupling between these atoms,
respectively, are used in these experiments. For through-space experiments or multiple bond Jtransfers, magnetization transfers during mixing times are indicated by curved arrows and all
involved nuclei are circled in red. Potential interresidue contacts are indicated with a dashed
green arrow. Where possible, the experiments are run using sensitivity enhancement and pulsed
field gradients described by Muhandiram and Kay (86). Solvent suppression can be implemented
using a variety of means (e.g., flip-back pulses, WATERGATE sequences, gradient pulses).
Where multiple pulses sequences are available, short experiments should be conducted to assess
which version works best (i.e., highest signal-to-noise) for the sample in question.
Sample-Experiment Parameters
It should be noted that it is not desirable to conduct all the experiments described below
using a single prepared sample (i.e., in the same buffer system). For instance, for NH-detected
experiments the buffer system should contain no more than 10% D2O, unless an H-D exchange
experiment is being run. If the experiments being run are CH-detected, as in the 1H-13C HSQC,
1

H-13C NOESY-HSQC or related experiments, then the buffer should be exchanged into buffer
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prepared in 100% D2O in order to decrease the contribution of residual water protons to the
spectrum. This reduction of water signal increases the likelihood that resonances near the water
frequency will be detected (often H") and can increase the receiver gain (because water protons
are not present) so that these experiments can have the maximum sensitivity possible. Another
important consideration for these experiments is to minimize or eliminate any non-protein
system components that are not deuterated. This includes using buffers that do not have protons
(phosphate instead of Tris), using deuterated detergents or lipids instead of nondeuterated ones,
and eliminating transfers of protonated molecules from other sources (e.g., trace amounts of
glycerol present in filter concentrators).
Acquisition Parameters
1

H pulse lengths, as well as the O1 (resonance frequency for the 1H channel) are

measured on each sample. All 13C and 15N pulse lengths are calculated from the measured 90˚
pulse lengths determined either on a standard sample of urea or on the actual experimental
sample. Typical experiment acquisition settings for the data matrix size would be 2048 x 48 x
128 (F3 x F2 x F1, where F3 is the direct dimension). Sweep widths in each dimension should be
truncated as much as possible to increase resolution (Hz/ppm). The resonance frequency of each
channel should be chosen to be in the center of the sweep width (for HNCO- 1H ~4.7 ppm, 13C
~176.0 ppm, 15N ~118.0 ppm). Last, secondary acquisition parameters (e.g., nd0/nd10,
FnMODE) should be set correctly prior to acquisition using the pulse program as a guide.
Processing Parameters
Processing NMR spectra was performed using Bruker’s Topspin software. However,
because processing depends to an extent on the judgment of the operator, processing is more of
an art than data acquisition. Despite the room for objectivity, there are general rules to follow
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when doing this. It is acceptable to truncate the time domain of any spectrum that has decayed
completely or where the end of the FID is noise. Datasets should be zero-filled no more than
once (2 x TD). Proper FnMODE flags should be set depending upon acquisition parameters.
Forward linear prediction is used in indirect dimensions to compensate for the lower number of
points taken in the interest of saving experiment time. The number of coefficients (NCOEF)
chosen for linear prediction is generally a number between 16-32, though some
recommendations indicate that this should be roughly equal to the number of peaks expected in
the spectrum. Post-acquisition referencing is done indirectly using DSS, either internally or
externally, as described in (87, 88).
2D Experiments
1

H-15N-HSQC (Heteronuclear Single Quantum Coherence)
The 1H-15N-HSQC is arguably the most important experiment in protein solution NMR.

While it is a simple experiment, providing only through bond correlations for 2 nuclei (89), the
spectrum itself provides a means for assessing conformational heterogeneity or changes in
sample conformation upon changes in sample conditions (pH, buffer, mutating residues).
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Figure 2.1 1H-15N-HSQC expected resonances. This experiment allows correlation of the
chemical shift of nitrogen with that of its attached proton. Residues with sidechains containing
nitrogens would generally show up in this experiment as well.
.
1

H-13C-HSQC (Heteronuclear Single Quantum Coherence)
Essentially the same experiment as the 1H-15N-HSQC above, the 1H-13C-HSQC provides

through bond correlations between 13C and its directly attached 1H atom(s). While the premise is
essentially the same, there are many more variations of the 1H-13C-HSQC than the 1H-15NHSQC. There are only two types of NH peaks in an 1H-15N-HSQC (backbone and sidechain
amide), but for the 1H-13C-HSQC, the carbons and protons cover a wider frequency range in both
dimensions. To make matters more complicated, aromatic C-H bonds have a different J-coupling
value and show up at a different frequency (in C and H) than the aliphatic C-H do, so a second
experiment with optimized values needs to be run to visualize the aromatic CH portion of the
spectrum. The differences come mainly from the desire to look differently at the more numerous
types of carbons in the spectrum, or at specific regions of the spectrum.

Figure 2.2 1H-13C-HSQC expected resonances. This experiment allows correlation of the
chemical shift of carbon with that of its attached proton(s).
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3D Backbone Experiments
Through bond correlations of carbon resonances to backbone amide resonances are the
basis of assigning particular NH resonances to residues in the protein sequence. This assignment
approach requires the collection of multiple datasets that correlate 1H-13C-15N resonances in a
through bond fashion. There are several approaches to sequential protein assignment; a
discussion of the merits of each is beyond the scope of this text but is covered elsewhere (90,
91).
HNCO
This interresidue experiment allows correlation of the i-1 carbonyl carbon resonance with
the i NH (92). It has the highest sensitivity of all the 3D backbone experiments, and the 2-3 plane
(NH plane) should generally (but not always) replicate the 1H-15N HSQC. The spectrum should
yield one carbon peak per NH, so if two or more peaks are seen at a particular NH frequency,
multiple conformations for that residue may exist (assuming there aren’t two or more
overlapping amide resonances at this frequency). Resonances missing would be any residue
preceding a particular residue that does not have intensity in the 1H-15N HSQC (i.e., proline or
flexible residues). This experiment has the highest sensitivity of the HN-detected 3D triple
resonance experiments, so all expected peaks should be seen with good resolution after 8 scans
before proceeding to the other 3D experiments. Magnetization begins on the amide proton, is
transferred to the attached nitrogen using an INEPT transfer using the HN J-coupling, then to the
carbonyl carbon using the NCO one-bond J-coupling. Then magnetization is transferred back to
the amide nitrogen for detection. The 2-3 plane will recreate the 1H-15N HSQC, the 1-3 plane
shows the dispersion of the carbonyl carbon resonances.
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Figure 2.3 HNCO magnetization transfer. This experiment correlates the chemical shifts of the
i nitrogen and proton with that of the i-1 carbonyl carbon.
CBCACONH
Sidechain assignment begins with this through-bond interresidue experiment that
correlates the i residue NH with the C# and C" resonances of the i-1 residue. After the HNCO, it
has the second highest sensitivity of the 3D backbone experiments described. Magnetization
transfer begins with a 1H to 13C INEPT transfer to the C#/C" carbons, then to the C#, then a
transfer through the carbonyl carbon to the amide nitrogen using the appropriate 1 bond Jcoupling for each bond. An INEPT transfer back to the attached amide proton from the nitrogen
allows detection. All experimental peaks are positive, and the 2-3 plane should recreate the 1H15

N-HSQC. The 1-3 plane demonstrates two carbon resonances for each NH resonance,

representing the C# and C" peaks. Similar information can be obtained by the HNCOCACB
experiment.
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Figure 2.4 The CBCACONH experiment. This experiment correlates the chemical shifts of the i
nitrogen and proton with that of the i-1 C!/C" carbons.

HNCACB
Each of the previous experiments are solely interresidue experiments, so an experiment
that contains resonances from both the i and i-1 C# and C" resonances is necessary for sequential
reside assignment. Several possibilities are available to choose from when correlating inter- and
intra-residual C#/C" resonances to a single NH resonance in the same experiment, but the
experiment used in this series is the HNCACB experiment (93). Magnetization begins on the
amide proton, is transferred to the attached nitrogen, then to the C# using an average of the Jcouplings from the i and i-1 (2 bond) N-C# couplings. Magnetization is then transferred to the
C" using the C#-C" coupling. Then everything happens in reverse to transfer magnetization back
to the amide proton for detection. This experiment yields peaks in the carbon dimension that are
180˚ out of phase, which allows the phasing of the C# resonances (~65ppm-45ppm) positive and
the C" resonances (~42ppm-18ppm) negative. Another important consequence of this is that
processing the 2-3 plane will generally sum to zero (for a single scan) because of the addition of
positive and negative peak intensities, so recreation of the 1H-15N HSQC is not possible. The 1-3
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plane should overlap with the 1-3 plane of the CBCACONH above, albeit with twice as many
peaks for each NH resonance.
Particular acquisition parameters to which attention should be paid are the shaped carbon
pulses. These are generally calculated from the carbon 90˚ pulse, so if the 90˚ pulse is not
correctly calibrated then the shaped pulses may be incorrect as well, causing phase errors in the
carbon dimension and other spectral artifacts (e.g., zero-quantum effects).

Figure 2.5 The HNCACB experiment. This experiment correlates the chemical shifts of the i
nitrogen and proton with that of the i and i-1 C!/C" carbons.
3D Sidechain Experiments
While the above experiments are sufficient for assignment of the backbone atoms to
particular resonances in the various spectra, because high-resolution structure calculation
requires identification of nuclear Overhauser effect spectroscopy (NOESY) crosspeak
components, assignment of as many protons in the protein as possible is essential. Therefore,
using the already identified backbone resonances as a starting point, magnetization transfers are
extended to atoms further out the sidechain for collection and identification of these resonances.
Generally, these experiments have lower sensitivity than the HNCO backbone experiment.
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HBHACONH
This experiment is essentially the same as the CBCACONH experiment described above,
but instead of evolving and recording the i-1 carbon chemical shifts, the i-1 H#/H" proton
chemical shifts are recorded. Due to its relatively high sensitivity among the sidechain
experiments, it should be run first.

Figure 2.6 The HBHACONH experiment. This experiment correlates the chemical shifts of the
i nitrogen and proton with that of the i-1 H!/H" protons.
HCCCONH
The HCCCONH experiment correlates all sidechain protons of aliphatic i-1 sidechains to
the i NH resonances. It uses an isotropic 13C mixing sequence to exchange magnetization
between the sidechain carbon atoms (94, 95). Magnetization is then transferred through the
carbonyl carbon to the i NH for detection. An important acquisition parameter to pay attention to
is the length of the isotropic mixing sequence.

&&

Figure 2.7 The HCCCONH experiment. This experiment correlates the chemical shifts of the i
nitrogen and proton with that of the i-1 sidechain protons.

CCCONH
This experiment is closely related the the HCCCONH above, but instead of recording the
chemical shift of the aliphatic sidechain protons, the chemical shifts of the sidechain carbons are
recorded instead. As above, the length of the isotropic mixing period should be paid particular
attention.

Figure 2.8 The CCCONH experiment. This experiment correlates the chemical shifts of the i
nitrogen and proton with that of the i-1 sidechain carbons.
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3D Through-Space Experiments
High-resolution 3D structure calculation depends upon determining the relative positions
of all of the molecule’s atoms in space. In X-ray crystallography, the X-rays passing through the
protein crystal cause a diffraction pattern that gives a picture of the relative position of these
atoms in space. In NMR spectroscopy, this through-space picture is taken using correlations
between different protons in the sample. These experiments utilize the Nuclear Overhauser
Effect and are called ”NOESYs” (Nuclear Overhauser Effect SpectroscopY). They use various
magnetization transfer schemes to isolate different species of protons (amide, aliphatic, etc) but
ultimately rely on a “mixing period” where different protons are allowed to exchange
magnetization. For instance, the 1H-15N-NOESY-HSQC is an experiment where all sample
protons are correlated to NH protons. This is to say that it examines all protons that are within 6
Å (or so) of an amide proton. The mixing time controls how far the detection distance is;
generally, shorter mixing times will generate less NOESY cross peaks (and cover less molecular
distance) than longer ones will. Mixing times should be optimized on a per sample basis,
generally larger molecules will have shorter optimal mixing times, but other factors such as
buffer composition come into play here as well.
NOESY-1H-15N-HSQC
This experiment combines a 1H-1H NOESY module with an 1H-15N HSQC module. This
means that first, magnetization is exchanged between all protons in the sample, then in the 1H15

N-HSQC, magnetization is detected through the NH moiety using an INEPT transfer. In this

way, we filter all of the NOE contacts that were made in the first module through the HSQC
module so that we’re only seeing the information exchange between protons that make contact
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with the NH proton. Ideally, most of the i sidechain protons should make contacts with the i NH
protons. In the figure below, these are denoted by solid red arrows. Potential contacts are
contacts that may occur over longer distances from neighboring spin systems, and are indicated
by dashed green arrows. Potential contacts are generally governed by secondary, tertiary, and
possibly quaternary structural folds and intensity of these may be modulated by judicious choice
of mixing time.

Figure 2.9 The NOESY-1H-15N-HSQC experiment. This experiment measures through-space
contacts between amide protons and all other protons in the sample.

NOESY-1H-13C -HSQC
In a fashion similar to the 15N-NOESY-HSQC experiment above, this experiment
combines a 1H-1H NOESY module with an 1H-13C-HSQC module. Correlations are detected
between different protons attached to carbons, and nitrogens if the sample is not in 100% D2O.
n.b., In the figure below (2.10), I have omitted contacts between the amide proton and nearby
CH groups. Because this experiment is usually conducted in 100% D2O, amide protons would be
expected to exchange with deuterons and therefore be invisible. However, if for some reason the
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experiment was not conducted in D2O, or H-D exchange did not occur, these contacts would be
expected in the spectrum.

Figure 2.10 The NOESY-1H-13C-HSQC experiment. This experiment measures through-space
contacts between aliphatic protons and all other protons in the sample.

CN-NOESY
This experiment is also known as the HSQC-NOESY-HSQC because it sandwiches a
NOESY experiment between an 1H-13C-HSQC module and an 1H-15N-HSQC module to allow
detection through the amide NH resonances only those protons that are attached to a carbon (85).
In this way, the flow of magnetization proceeds from carbon to its attached proton, then a
NOESY mixing period occurs where protons are allowed to exchange magnetization, and finally
detection occurs on the amide proton. This experiment deviates from a traditional NOESY in that
the chemical shift axes recorded are carbon, nitrogen and the amide proton instead of two
protons and one heteronucleus. In a traditional fully 13C15N labeled protein sample, this
experiment would not record any additional information when compared to a NOESY-15NHSQC. However, in a homodimeric system where one monomer is 13C labeled and the other is
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N labeled, this experiment allows the transfer of NOEs in an intermonomer fashion, facilitating

the identification of residues lining the dimer interface. One piece of information that is missing
from this experiment is stereospecific information from the donating proton, assuming a
particular carbon has multiple unique protons. This information can be regained by running the
complementary NC-NOESY (see below). Important parameters are the J-couplings for the
involved heteronuclei-proton pairs and the mixing time for the NOESY period.

Figure 2.11 The 13C15N-NOESY experiment (aka. HSQC-NOESY-HSQC). This experiment
measures through-space contacts between the amide proton and protons attached to carbons,
but records the chemical shift of the carbon atom instead of the proton.

NC-NOESY
This is the complementary experiment to the CN-NOESY above (85), but it swaps the
1

H-15N-HSQC and the 1H-13C-HSQC modules so that detection occurs through the CH instead of

the NH. Important experimental considerations are as for the CN-NOESY above, but it is
important to note that the signal to noise may be lower than the CN-NOESY because the NCNOESY contains more stereospecific information.
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Figure 2.12 The 15N13C-NOESY experiment (aka. HSQC-NOESY-HSQC). This experiment
measures through-space contacts between aliphatic protons and protons attached to nitrogens,
but records the chemical shift of the nitrogen atom instead of the proton.

X-Filtered NOESY-HSQC (or HSQC-NOESY)
The last, and arguably most complicated experiment is the X-filtered NOESY-HSQC.
Originally developed to study points of interaction between parts of a 2-component system (84),
it has more recently been used to determine which residues line the interface of TM helix
homodimers (81). Intermonomer proton-proton NOEs are collected using the X-filtered NOESYHSQC (84) and a sample that has half unlabeled and half 13C15N-labeled monomers (see figure
below-isotopically labeled atoms are green or blue). NOEs are transferred for one unlabeled
molecule to the labeled one. Because this experiment depends upon detection of NOEs arising
from unlabeled molecules, it is especially important to be certain that there are no components of
the system that contain these types of molecules (residual unlabeled detergent, glycerol, buffer,
or referencing agent). A related experiment switches the NOESY and the HSQC blocks of the
experiment such that the experiment becomes an HSQC-NOESY. The information collected is
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the same, however, because the NOESY crosspeaks are collected in the direct dimension (F3),
greater resolution can be obtained.

Figure 2.13 The X-filtered NOESY experiment. This experiment measures through-space
contacts between of the protons of one unlabeled monomer and one isotopically labeled
monomer.

Other Useful Experiments
HNCANNH
Allows the correlation of the i-1 and i+1 nitrogen resonances with the i NH (96). It is
particularly useful for samples where protein sequences or C#/C" resonances are degenerate and
correct assignment is precluded. The information produced allows one to walk through the
1

H15N-HSQC in a sequential fashion. While it is useful, for many samples it will have low

sensitivity.
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HNCACO
This experiment correlates the i NH with the i and i-1 carbonyl carbon resonances. It is
useful in samples with proline residues, where the i-1 CO resonance for residues preceding
proline are not visible in the HNCO experiment.
TOCSY-HSQC
This experiment correlates the i sidechain protons to the i NH, and can be useful if
sidechain protons are missing in the HCCCONH experiment.
HCC-TOCSY
This experiment correlates sidechain carbons with one of the sidechain CH moieties. It
can be useful for sidechain assignment, but in samples with multiple residues having similar
chemical shifts, resonance overlap can preclude proper assignment.
HCH-TOCSY
This experiment correlates sidechain protons with one of the sidechain CH moieties. As
with the HCC-TOCSY above, resonance overlap can prevent specific resonance assignment.
Relaxation NMR Experiments
Fluctuations about the NH bond can be used to determine the relative flexibility of the
NH of each residue in the sample using the heteronuclear NOE experiment (97). T1 (spin-lattice)
or T2 (spin-spin) relaxation parameters for each 15N in the sample can be measured with the T1
relaxation and the T2 relaxation experiments (97).
Solvent Accessibility
NOEs of backbone or sidechain NH moieties to solvent (e.g., water) can be measured
using pulse sequences conaining the CLEANEX pulse sequence module (98).
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Peak Assignment
All datasets were processed with Topspin 2.0 and either internally or externally
referenced to the DSS methyl peak as described previously (87, 88). Processed data were then
converted into a .ucsf file using the “bruk2ucsf” file conversion program in Sparky v3.113 (99).
All spectra were loaded into Sparky, saved as a single project file and appropriate axes were
synchronized using the “synchronize views” command window. Peaks in each experiment were
picked and then assignments were made manually using the protein sequence and the 1H-15NHSQC, CBCACONH and HNCACB experiments. Where degeneracies or discrepancies arose,
the NOESY-15N-HSQC spectrum was used to determine sequential assignment of a particular
NH resonance based on proximity. Also useful for this purpose was the HNCANNH experiment
(96). Once assignment of backbone N, H, C# and C" atoms was complete, the assignments of
carbonyl atoms were made using the HNCO spectrum. Sidechain atom assignment began with
the HBHACONH experiment, then were finished with the (H)CCCONH and the CCCONH
experiments (94). Peaks for the various NOESY spectra collected were peak picked for each
strip within the Sparky data model, but were not given resonance assignments.

Structure Calculation
Sparky peaklists, resonance assignments and ucsf spectra were transferred into the
Collaborative Computing Project for NMR (CCPN) data model (100) to facilitate structure
calculation. CCPN exports data directly into Aria2.3 (101), the program used to assign NOE
spectra during the structure calculation process. Aria2.3 was used to automatically assign peakpicked (but unassigned) NOESY-13C-HSQC spectra and Crystallography and NMR System
(CNS) 1.21 (102, 103) was used as the structure calculation engine. Details of restraints and
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structure parameters are discussed in Chapter 3, but briefly, constraint lists for structure
prediction consisted of dihedral angle prediction and hydrogen bond lists for helical TM
structure (i C=O/i+4 H-N bonding), derived from the chemical shift analysis (104). Initial rounds
of structure calculation included these constraints and 1 or more of the NOESY spectra described
above. Processing and structure calculations were performed on an Apple MacBook Pro with OS
X 10.6.8, a 2.4 GHz Intel Core 2 Duo processor and 4 GB of RAM.
CCPN
The Collaborative Computing Project for NMR (CCPN) has produced a multifunctional
software package for processing of NMR data (100). In addition to spectrum organization and
peak assignment, there are a variety of tools incorporated into the software package that aid in
structure calculation. DANGLE (105) is a dihedral angle prediction program that works in a
manner similar to TALOS (106). Using the resonance list and the protein sequence, dihedral
angles are predicted from the chemical shifts of the backbone atoms H, N, CO, C#, C", H# and
stored within the project directory for later export to Aria2.3. Tools for creating other constraints
used in structure calculation, such as hydrogen bonding lists or other distance restraints are also
incorporated into the software package.
ARIA2.3/CNS 1.21
Ambiguous Restraints for Iterative Assignment (Aria2.3) is a program that is used to
analyze NOESY spectra in the context of a fully assigned resonance list to determine NOE peak
contributions, make assignments to these NOEs and then use this information iteratively to
calculate protein structure (101). Through successive iterations of structure calculation, correct
NOE assignments would be enforced and carried through to the next rounds of calculation and
incorrect ones would be discarded, ultimately producing a list of correct NOE assignments and
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an accurate protein structure. Aria2.3 works with CNS (102, 103) where Aria2.3 calibrates and
assigns NOEs at the beginning of each structure calculation iteration and CNS uses this
information in the structure calculation.
To do this, Aria2.3 source code is compiled with CNS source code to make an executable
program. The Aria2.3 gui window allows easy incorporation of project data from a saved CCPN
project or independently from user modified xml files. Constraint lists can be read into Aria2.3,
along with the molecule information, and CNS iteration parameters can be set. These data can be
saved-Aria2.3’s output is an xml file with links to all of the constraints and all the information
that CNS needs to run structure calculations. Once saved, the script is setup and then activated
from an X11 terminal window. At this point, CNS takes over and runs iterations, returning
structures and data after each step. These results can be read back into CCPN to refine the data
model in order to perform more precise structure calculations.
NOE Assignment with Aria2.3
Crosspeaks in NOESY spectra contain two pieces of structural information. The
frequencies of the crosspeak in the relevant spectral dimensions reveal the identity of the two
interacting spins, and the crosspeak intensity generally provides information about the distance
separating those spins. The combination of these two pieces of information allows structure
calculation. In theory, for a given structure, a “correct” set of NOE assignments exists where the
identity and distance information for all peaks are self-consistent, that is, they are derived from
and support calculation of a single structure. A typical NOESY spectrum from even a small
protein can contain hundreds of NOE crosspeaks, making manual assignment arduous. Aria2.3
increases efficiency and accuracy of NOE spectrum assignment by automatically calibrating
NOE crosspeaks and assigning them using the resonance list (101). Assignments that cannot be
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unambiguously assigned are given an ambiguous assignment, where several possible
assignments are treated as a single restraint. Then, these assignments are evaluated by a round of
structure calculation. Through successive iterations of assignment and structure calculation,
structural and NOE peaklist ambiguity are reduced, with correct assignments saved and incorrect
ones discarded, resulting in structural refinement.
Input data for the structure calculation begins with the molecular system as defined by
CCPN. This consists of the protein sequence and number of peptide chains in the system. The
chemical shift list for each chain is read in, and the symmetry is set for “C2” symmetry,
representing a symmetric homodimer system. Constraint lists begin with dihedral angle
predictions for each chain, as well as hydrogen bond lists for the #-helical region of each TMD.
Peak-picked NOESY spectra are added for each through space experiment being used for the
calculation. An unambiguous constraint list consists of NOE contacts from manually calibrated
NOE spectra such as the CN-NOESY and any NOE crosspeaks that can be unambiguously
assigned to specific, non-overlapping resonances. All manually calibrated NOEs are sorted into 3
categories, weak, medium, and strong based upon the intensity of the crosspeak. Where possible,
peak intensities are calibrated using an internal standard, such as crosspeaks within the leucine
sidechain (e.g., H# -> H$). All lower bounds for manually calibrated crosspeaks were set to 1.8
Å. Upper bounds added 0.6 Å to the calibrated value. Other structural constraints used are the
dihedral angle prediction for the molecular system and the hydrogen bond constraint list.
Structure Calculation
Structures were calculated using Aria2.3 default settings (107). Unambiguous constraints
enter the calculation in the first round of calculation. Default iteration parameters consist of 8
rounds of structure calculations, with 20 structures generated each round. Refinement of the
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resulting structures in explicit solvent occurred using a shell of water molecules. Analysis of the
20 structures generated uses the seven lowest energy structures from each round to create an
ensemble average. Procheck2 was used to evaluate the dihedral angles of each average structure
as well as the root mean square deviation (RMSD) of backbone atoms and angles (108, 109).
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Chapter 3-Structure of the Erythropoietin Receptor Transmembrane Domain Dimer
While there is compelling evidence that the Epo receptor exists as a pre-formed dimer,
and the TMD mediates dimerization, several questions still remain unanswered. What is the TM
dimerization interface? Does the murine Epo receptor TMD follow the proposed interface with
Leu and Ser residues mediating dimerization (61)? How is it that the three amino acid difference
between the mouse and human receptors influence 1) gp55-P binding and activation, and 2) the
dimerization propensity seen by Ebie and Fleming (65)? Do the mouse and human receptors
share the same interface? Most important of all, how is it that ligand binding is transmitted
through the TM dimer to the ICD in order to activate Jak2?
To begin to define the role of the TMD in the structure and function of the Epo receptor,
structural studies were performed on the smallest independently folding region, the TMD
sequence from residues 220-248, referred to as muEpoR220-248 (Figure 3.1). My studies began
with the murine sequence. The murine sequence was selected for structural studies on the basis
of more available biochemical and biophysical data. The construct is expressed as a fusion
protein and contains both the putative TMD and several residues from the region that connects
the extracellular D2 domain with the TMD (Ala220-Asp224). The cleaved, purified peptide is
solubilized in a membrane mimetic system and used for solution NMR and other biophysical
experiments.

Figure 3.1 Sequence of the muEpoR220-248 peptide. muEpoR220-248 captures the entire TMD
(P225-L247) and a small segment of the extracellular JM domain sequence (in red) that overlaps
with the C-terminus of the ECD crystal structure (PDB ID:1CN4). Proteolytic cleavage of the
fusion protein leaves two non-native amino acids (Ser-Asn) attached to the N-terminus.
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Choice of Membrane Mimetic System for Solution NMR Studies on Monotopic Membrane
Proteins
Many decisions need to be made when undertaking biophysical studies on a particular
protein. Solvent, buffer, pH, salt concentration, minor buffer components, and cofactors are
several of the parameters that need to be considered for collection of biologically relevant data.
Additionally, system components may not be compatible with certain techniques at the desired
concentration, if at all. In an ideal situation, a preparation would resemble the protein in vivo,
possessing the same structural features and any native biological activity. Finding the appropriate
milieu can be difficult, even for soluble proteins. For membrane proteins, the natural
hydrophobic character of TMDs presents an additional complexity as they are not soluble in
water. Organic solvents, lipids, detergents (110) and amphipols (111) are typically used to
solubilize membrane proteins.
Solution experiments can be run on peptides in organic solvent (112, 113), but any
hydrophilic portions of the peptide may not adopt native structural features and TM
oligomerization may be adversely affected (114). Another method for solubilizing hydrophobic
TMDs involves simulating the hydrophobic environment of the lipid bilayer. This is possible by
including molecules that have a hydrophobic and a hydrophilic domain. Such molecules would
include lipids, detergents (110) and amphipols (111). Lipids normally self-assemble into
multilamellar vesicles (MLV) consisting of many stacked bilayers; these MLVs are too large to
be useful in solution NMR. Small unilamellar vesicles (SUVs) are smaller, but still too large and
unstable to be used for solution NMR of integral membrane proteins; they are more commonly
used to study soluble proteins that interact with lipid bilayers (110). Isotropic bicelles contain
long and short chain lipids, typically 1,2-dimyristyl-sn-glycerophosphocholine (DMPC) and 1,2-
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dihexanoyl-sn-glycerophosphocholine (DHPC) at a ratio of 1:4. These are becoming more
popular for solution NMR studies for integral membrane proteins, as they may lessen #-helical
structure distortion or allow the protein to retain some native activity (115). However, bicelles
are still about twice as large as a micelle, which may necessitate use of deuteration and/or
TROSY type pulse sequences (116). Additionally, lipids are more expensive than detergents, and
deuterated lipids may be much more costly if they are available at all.
Detergents possess a hydrophilic head group and a hydrophobic “lipid-like” tail; these
molecules spontaneously form micelles in aqueous solutions that have a hydrophobic interior
(tails) and a hydrophilic surface (head groups). Many different detergents are available; they
differ in the constituent groups. Typically, the molecular weight of the micelle plus the protein of
interest is small enough to be studied by solution NMR (110).
Solution NMR studies of TM proteins in detergents are becoming increasingly common.
Structures or structural features of entire TM proteins (117) or portions of larger polytopic TM
proteins (116, 118) are being studied with increasing frequency due to technological
advancements in spectrometer/probe design (e.g., cryoprobes) or pulse sequence development
(TROSY) (119). Advances in both fields allow the study of larger, more quickly relaxing
systems. These methods are particularly suited to studying TM dimers. Judicious sequence and
detergent choice allow the molecular weight of the complex to remain under 40 kDa, small
enough to be studied by traditional solution NMR methods. This size is ideal, as crystallization
of these systems has not progressed as quickly as for multitopic membrane proteins (e.g.,
GPCRs) (120).
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Regardless of what membrane mimetic is chosen, the complex under study must
approximate the structure (and if possible function) of the biologically native sample. Many
single TM receptors signal productively through a dimeric intermediate. Receptor interactions in
single-pass membrane proteins are often mediated by sequence specific contacts in the TMD
(82, 121). TM dimerization has been shown for the ErbB receptors, which are known to dimerize
in lipid bilayers (122), the ephrin receptors (123, 124), and glycophorin A (125), among others.
The solution structures of TM homodimers for Eph2A (126), the CD3 TCR %% domain (127), and
BNIP3 (81, 128) have been solved.
However, important differences exist between lipid bilayers and detergent micelles that
may bias structural studies. First, micelles have a greater degree of surface curvature that may
adversely influence the structure of proteins solubilized by detergent micelles (129). Second, the
width of the hydrophobic portion of the micelle may not match the native lipid environment,
allowing or inducing changes in helix tilt or changes in packing of helices. Third, the packing
between the hydrophobic detergent tails and the hydrophobic exposed amino acid sidechains
may be suboptimal (130). In the end, if possible, it is best to correlate biophysical and structural
data from studies performed in lipid bilayers and studies performed in detergent micelles to
minimize or eliminate bias induced by the system chosen.
These studies use dodecylphosphocholine (DPC) as the membrane mimetic system. DPC
is the most commonly used mimetic for solving membrane protein structures (110). It also has
been widely used for AUC studies on TM proteins (131). DPC mimics several characteristics of
the lipid bilayer. The zwitterionic phosphocholine headgroup is the most common headgroup of
all phospholipids in the typical eukaryotic cell membrane (132). The width of the hydrophobic
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portion of a DPC micelle (25.5-27.5 Å) (133) as measured by small-angle X-ray scattering is
roughly the same as the hydrophobic portion of a lipid bilayer (~25-30 Å) (132).
AUC Measurements Confirm Dimer Formation of muEpoR TM Peptides in DPC
The existing cellular, biochemical, and biophysical data regarding dimerization of the
EpoR TMD has been discussed above. Once reconstituted into DPC detergent micelles, our
TMD-containing peptide was studied by analytical ultracentrifugation (AUC). Because of
difficulty studying very small molecular weight proteins in detergent micelles by AUC, we used
the slightly larger muEpoR218-268 peptide. AUC results (Figure 3.2) demonstrate that in DPC
micelles, the molecular weight of the complex is ~12 kDa, approximately twice the weight of a
muEpoR218-268 monomer (5.9 kDa).
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Figure 3.2 AUC of muEpoR218-268 in DPC micelles. The muEpoR218-268 peptide was solubilized
in DPC detergent micelles, 50 mM Tris, 100 mM NaCl, 15 mM DPC, pH 7.5 at peptide
concentrations of 60, 70 and 180 µM. Centrifuge speeds used were 40,000 rpm and 48,000 rpm.
Global curve fit analysis reveals that the MW of the complex is ~12 kDa, consistent with a dimer
of muEpoR218-268. Shown is a representative curve and residuals.

muEpoR220-248 NMR Measurements
For these experiments, the sequence of the mouse EpoR TMD (muEpoR220-248, Figure
3.1) along with a few EC-JM residues were cloned into the His-MBP vector (Chapter 2),
expressed and purified. muEpoR220-248 represents the smallest independently folding region of
the receptor. The 1H-15N-HSQC of the muEpoR220-248 is presented in Figure 3.3. The spectrum
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exhibits well-resolved, uniform peaks indicative of a homogeneous sample preparation. The
spectrum shows the expected number of peaks, an indication that the sample under study is either
monomeric or a symmetric oligomer. If the system under study was not structurally
homogeneous, or an asymmetric oligomer, multiple peaks would be expected for each amino
acid. Three-dimensional NMR measurements allowed the assignment of each peak in the
spectrum to a particular amino acid (with the exception of Pro225). Chemical shift analysis
carried out on the fully-backbone assigned sample indicates that the muEpoR220-248 peptide is "helical from residues Pro225-Leu246 (Figure 3.4). Circular dichroism spectroscopy of the
muEpoR220-248 peptide solubilized in DPC micelles confirms these measurements.

Figure 3.3 1H-15N-HSQC of muEpoR220-248. The 1H-15N-HSQC demonstrates good peak
resolution and sensitivity, indicating sample homogeneity. The spectrum was collected on a 700
MHz spectrometer at 313 K with 32 scans. Sample is ~1 mM protein, 10 mM sodium phosphate,
pH 7.0, 200 mM d38-DPC, 10% D2O (v:v).
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Figure 3.4 Secondary structure of muEpoR220-248 in DPC micelles from NMR measurements.
Chemical shift analysis of NMR measurements predicts dihedral angle values consistent with
alpha-helical secondary structure between P225-L246. The chemical shift analysis was made
using the program DANGLE (105).

Unusual Chemical Shifts of muEpoR220-248 TM Polar Residues
One curiosity that arose from analysis of the chemical shifts of the TM residues in
muEpoR220-248 is the observation of downfield shifted 13C# resonances for Ser and Thr residues
within the TMD (listed in Table 3.1). While the C! chemical shifts seem to be within one
standard deviation of the mean value, the C# resonances for Ser/Thr residues in the muEpoR220248

peptide in aqueous solution (10 mM sodium phosphate, pH 7.0) are shifted downfield by

more than 2 standard deviations from their mean values. Hypothesizing these downfield shifts
were directly related to dimerization, a muEpoR220-248 sample was prepared in organic solvent
(90% trifluoroethanol:10% CDCl3, v:v), backbone resonances were measured by NMR and
assigned to specific amino acids. Trifluoroethanol (TFE) has been used for NMR data acquisition
on TM peptides previously (134); it is expected to retain, but not induce #-helical structure for
peptides, yet disrupts intermolecular interactions (114). Interestingly, this TFE preparation of the
muEpoR220-248 peptide exhibits chemical shifts of the Ser/Thr C# atoms in more upfield
positions. Secondary structure influences chemical shift such that C# resonances shift downfield
and C" resonances shift upfield. However, because both peptides are #-helical and differ only in
oligomeric status, we suggest that these residues may be involved in or affected by dimerization.
The unusual downfield shift of the C# resonances could be due to several factors. The BMRB
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keeps detailed records of all chemical shifts (http://www.bmrb.wisc.edu/ref_info/statsel.htm),
and outliers (> 3 SD from the mean) are flagged separately. Interestingly, of the first six NMR
structures in the BMRB with outlying Ser C" chemical shifts downfield of the mean value, all
are in #-helical structure. Three (PDB IDs:1QQY, 1R7J, 1ZGG) are within hydrogen bonding
distance to an acidic residue side chain (Asp, Glu), and two others (PDB IDs:1HA8, 2KZT) are
within 6 Å of several polar sidechains (Gln, Arg, Lys). This observation would suggest that a
combination of secondary structure and polar environment can cause such a chemical shift
deviation. If the polar residues mediate an interface between two #-helical monomers, the
proximity of the sidechain OH groups may create a polar environment able to perturb the
chemical shifts in the manner seen.
Residue

C", DPC

C", TFE

C!, DPC

C!, TFE

S221

59.054

57.875

63.661

61.313

T229

68.434

65.532

68.083

67.009

S231

63.708

60.367

62.891

60.367

S238

63.753

60.686

62.688

60.686

T242

68.33

65.2

67.747

66.698

S248

61.068

56.125

65.056

61.926

BMRB
Avg Ser/Thr (sd)

Ser: 58.73 (2.08), Thr: 62.22 (2.59)

Ser: 63.8 (1.48), Thr: 69.74 (1.65)

Table 3.1 Unusual chemical shifts of TM polar residues suggests dimerization. The C!
resonances of TM polar residues are downfield shifted from non-TM polar residues (shaded
region). In particular, the Ser231/Ser238 C! resonances are shifted more than 2 standard
deviations from the mean. The EC-JM (Ser221) and TM (Ser248) are presented for comparison,
these remain unshifted. Average values were obtained from the BMRB
(http://www.bmrb.wisc.edu/ref_info/statsel.htm).
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Structural Model of the EpoR TM Dimer Based Upon Intermonomer NOE Contacts
CN-NOESY
Perhaps the most compelling evidence for a dimer interface driven by polar sidechain
interactions comes from specific NMR measurements using a sample that contained an
equimolar ratio of 15N12C-labeled muEpoR220-248 and 14N13C-labeled muEpoR220-248. The CNNOESY experiment (85) transfers magnetization from an H-C group to an H-N group. Because
one monomer of the dimer is labeled with 13C and the other monomer is only labeled with 15N,
NOEs are transferred across the dimer interface. Contacts made to either 12C- or 14N-containing
peptide are effectively filtered out. Representative strips of the spectrum are presented in Figure
3.5. In these measurements, contacts are observed between the 13C-attached sidechain protons
and amide nitrogens of Ser231, Val235, Ser238, Thr242, and Ala245, indicating these residues
line the dimer interface. It is important to note that in general, stronger NOEs for a given residue
are made for carbon atoms further out on the sidechain (e.g., Val235 C#1, C" > C"), which
would be expected as those atoms are closer to the opposite amide in space. All strips show
variable intensity peaks to unspecified Leu C" resonances. This is not surprising, as there are 12
Leu residues in the TMD and chemical shift degeneracy prevents accurate assignment.
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Figure 3.5 CN-NOESY NMR Spectra of muEpoR220-248 define TM dimer interfacial residues.
CN-NOESY spectra of 15N12C muEpoR220-248 mixed with 14N13C muEpoR220-248 (1:1 molar)
demonstrate that S231, V235, S238, T242 and A245 line the TM dimer interface. The spectrum
was collected on a 700 MHz spectrometer at 313 K with 32 scans. Sample was ~2 mM total
protein concentration in 10 mM sodium phosphate, pH 7.0, 200 mM d38-DPC, 10% D2O (v:v).
CHI
Prior to conducting the NMR experiments, computational searches for low-energy
symmetric homodimers using the CHI computational modeling program (135) were conducted
on the murine EpoR TM sequence. The interhelical axis distance was specified at 9.5 Å and the
dielectric was set to 1, reflecting the relatively low permittivity of a membrane bilayer. More
left-handed symmetric interfaces were found than right-handed ones, though generally the
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energies were similar. The interface of the resulting symmetric structures generally contained at
least one polar residue making an interhelical hydrogen bond. Interestingly, one of the lowestenergy left-handed structures (Figure 3.6) has Ser231, Val235, Ser238, Thr242, and Ala245 in
the dimer interface. This low-energy interface was also found in computational searches that
specified the interhelical axis distance at 10 Å.

T229

S231

V235

S238

T242
A245
S248
Figure 3.6 CHI computational modeling predicts a low-energy dimer interface. Computational
searches for symmetric, low-energy structures using the muEpoR220-248 sequence yield a lefthanded coiled coil dimer with S231, V235, S238, T242, and A245 lining the dimer interface. The
separation between the axes of the TM helices in the dimer (input parameter) is fixed at 9.5 Å.
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X-Filtered NOESY
The protein structure calculation depends upon collecting through-space NOE datasets.
This requires proper and complete assignment of backbone and sidechain atom resonances.
While the results of the CN-NOESY described above provide a low-resolution picture of the
dimer interface, it suffers from the lack of stereospecific information regarding proton contacts.
Two experiments were used to gain a higher resolution picture of the muEpoR220-248 homodimer.
First, the 1H-13C NOESY-HSQC provides distance information for pairs of protons in the
sample. These can be ambiguous as to whether the NOE contacts are inter- or intramonomer, due
to the proximity of the residues in the interface. They can also be ambiguous if several atoms
have the same chemical shift. Intermonomer NOEs were collected for a 1:1 13C15N
labeled:unlabeled muEpoR220-248 sample in D2O sodium phosphate (10 mM), 200 mM d38-DPC,
using an NMR experiment that detects only NOEs transferred from an unlabeled to a labeled
monomer (84). A third NOE dataset, a 1H-15N NOESY-HSQC was collected with a sample in
sodium phosphate, pH 7.0, 200 mM d38-DPC, 10% D2O (v:v). Constraints from the CN-NOESY
experiment were manually sorted into strong/medium/weak crosspeaks by intensity and included
in the unambiguous constraint list. The other NOE spectra were assigned using the program
Aria2.3 and the assigned peaklist through successive iterations of structure calculations. Lists of
ambiguous and unambiguous NOE constraints were generated after each round of calculation.
The ambiguous NOE list was analyzed and converted to unambiguous NOEs, which are
automatically included in the structure calculation. Representative slices from the X-filtered
NOESY are presented in Figure 3.8. These data demonstrate that small and polar residues line
the interface of the EpoR TM helix dimer, confirming the results from the CN-NOESY
experiment (Figure 3.5). A final list of distance constraints was prepared from these assigned
NOE spectra, a partial list is available in Table 3.2.
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D224

S231
V235
S238
T242
A245

Figure 3.7 muEpoR220-248 dimer structure determined from solution NMR measurements.
Structure determination from NMR data of the muEpoR220-248 protein in DPC micelles reveals a
symmetric left-handed coiled coil dimer with S231, V235, S238, T242, and A245 lining the dimer
interface.

Spectrum

Residues

CN-NOESY

Ser231C" - Ser231HN
Val235C" – V235HN
Val235C# – V235HN
Val235C#1 – V235HN
Val235C#2 – V235HN
Ser238C" - Ser238HN
Ser238C# - Ser238HN
Thr242C" - Thr238HN
Thr242C# – Thr242HN
Ala245C" – Ala245HN
)-

Ala245C# – Ala245HN
X-Filtered NOESY
Ile227H#-Ile227H%
Ile227H#-Ile227H%
Val235H#-Val235H#
Val235H"-Val235H#
Ser238H"-Val235H"
Ser238H"-Ser238H#
Thr242H#-Thr242H#
Thr242H#-Ala245H"
Ala245H"-Val243H#

Table 3.2 muEpoR220-248 interhelical dimer contacts. Intermonomer constraints were generated
from the CN-NOESY experiment and the X-filtered NOESY. Each constraint was counted twice
(From monomer A to monomer B and vice versa).

*
*
*

*

*
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Figure 3.8 X-filtered NOESY of muEpoR220-248 defines TM dimer interfacial residues. 15N13C
muEpoR220-248 mixed with 14N12C muEpoR220-248 (1:1 molar) demonstrates that V235, S238,
T242, and A245 line the TM helix dimer interface. Asterisks mark diagonal peaks. The spectrum
was collected on an 800 MHz spectrometer at 313 K with 24 scans. Sample was ~2 mM total
protein concentration in 10 mM sodium phosphate, pH 7.0, 200 mM d38-DPC, 100% D2O.
TM Dimer Interface
The structure of the muEpoR220-248 in DPC micelles calculated from NMR measurements
reveals that polar residues line the muEpoR220-248 peptide TM dimer interface (Figure 3.7), with
hydrophobic Leu sidechains facing the hydrophobic detergent tails. This interface correlates with
low energy structures calculated from computational searches for symmetric TMD dimers. TMD
dimerization mediated by polar residues has been demonstrated by asparagine mutagenesis
studies of model polyleucine helices (136). Eilers et al. (20) have found that Ser and Thr residues
mediate tight packing of helices in left-handed coiled-coil dimers. Furthermore, a clinically
relevant mutation of the TpoR TMD (S505N) causes TM self-assembly in the TOXCAT system
(15). The S505N mutation has been found in patients with thrombocythemia (33). These
observations indicate that the TMD plays a critical role in receptor activation, and mutation of
S505 to asparagine causes receptor hyperactivity via TM-mediated oligomerization.
The TM dimer interface presented for the muEpoR220-248 TM dimer can be compared
with interfaces proposed in the literature. Gurezka et al. (61) first proposed that muEpoR TM
self assembly was mediated by a leucine heptad repeat (Leu zipper) based on sequence similarity
of the muEpoR TMD with self-assembling model peptides containing a Leu heptad repeat (61).
Ruan et al. (64) took this work a step further and demonstrated by asparagine scanning
mutagenesis that several Asn mutations of the TMD caused greater activity in the TOXCAT
system; these mutations followed a different heptad repeat pattern that included Ser231 and
Ser238 at the “a” positions and Leu234 and Leu241 at the “d” positions (SxxLxxx-SxxLxxx-A).
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However, characterization of the L241N mutation in the context of the full Epo receptor in BaF3
cells demonstrated that this receptor was not constitutively active, but could be activated by Epo.
Further work investigated mutation to asparagine of the other residues in the interface (Leu234,
Ser238, Leu241, and Ala245) in the context of the full receptor (77). Curiously, and without
explanation, Ser231 is omitted from this study. However, Thr242 is added, a residue not
previously thought to be in the interface. None of the asparagine mutants were constitutively
active and only T242N exhibited cell surface expression comparable to wild type. However,
even though Epo could activate T242N, the receptor’s cellular staining pattern differed from the
wild type EpoR. While the authors ultimately make comparisons between helix packing density
and biological activity, the results are interpreted as if asparagine were driving specific TM
dimerization, which is not clear as the results could also be due to receptor dimer clustering or
trimer formation. Asparagine can drive trimer formation, as seen in mutants of #IIb"3 integrin
(137), and asparagine containing TM peptides (138). Further examination of the TOXCAT
method demonstrates that asparagine insertions in the background of a leucine heptad repeat can
cause stronger than normal TOXCAT readings due to higher-order oligomer formation that may
mislead interpretation of results (139). This may be the case in the L241N mutant, which showed
TOXCAT assay results ~4 times higher than other asparagine mutants (64).
The interfaces defined by the Ruan et al. (64) and Becker et al. (77) studies differ from
the interface defined here by ~52°, but share the Ser231, Ser238, and Ala245 residues. However,
this would leave Thr242 outside the interface and exposed to the hydrophobic lipid environment.
This is in direct contradiction with the T242N results obtained by Becker et al. (77). While the
two Thr sidechains (one for each monomer) could back hydrogen bond to the helix backbone
(140), this would otherwise lead to an increase in energy equivalent to 0.5 to 2.0 kcal/bond (141).
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The interface presented here from NMR measurements satisfies as many of those hydrogen
bonds as possible by burying the polar residues in the dimer interface. In support of this model
the interface defined here is the only interface identified by Seubert et al. (76) that could be
activated by the viral TM protein gp55-P, which has been shown to activate EpoR through TMTM interactions (14).
Active Interfaces
The results from the muEpoR220-248 structure determination are presumed to be from the
inactive TM dimer interface. However, asparagine mutants determined by Becker et al. (77) that
are shared by this interface (Ser238, Val235, Thr242, and Ala245) are able to be activated by
Epo. If the active dimers have a different interface than the inactive dimers (as in TM rotation),
then the presence of asparagine should make it more difficult to activate, which does not appear
to be the case based on Epo response curves. These results suggest three possibilities: 1) the
activation is able to overcome presumed asparagine-induced dimerization, 2) the inserted
asparagine does not affect the inactive dimer interface, or 3) the inactive and active interfaces are
the same. None of the TM residues, when mutated to cysteine, caused constitutive activation,
though L241C, L244C, and A245C could be crosslinked to varying degrees (74). However, all
responded normally to Epo. The combination of these results suggests that some aspect of EpoR
activation with respect to the TMD dimerization is misunderstood, and more work remains to be
done.
Human Receptor TM Domain
It is unclear if the human EpoR TMD uses the same interface. NMR measurements (1H15

N-HSQC) conducted on the same segment of the human receptor huEpoR221-249 (numbering is

slightly different because of an single amino acid insertion in the ECD) demonstrates a very
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different spectrum (Figure 3.9). Differences of this magnitude would not be expected from a
sequence that differs in only 3 amino acids in the center of the helix but uses the same
dimerization interface. This is especially true for residues not in the interface or at the ends of the
helix; if the dimerization interface remained the same, then those residues should be in a
relatively similar environment in both peptides. This result suggests that either the dimerization
interface has changed, or the huEpoR221-249 is no longer a dimer. However, AUC studies have
demonstrated that the huEpoR TM dimerizes in detergent micelles (65), and other studies have
determined a propensity of the huEpoR TM sequence to self-associate (19). If the human
receptor has a different TM dimer interface than the mouse does due to the loss of Ser238, then
this would suggest that Ser238 is important for dimerization, and explain the inability of the viral
TM protein gp55-P to activate the human EpoR (39).
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Figure 3.9 Comparison of muEpoR220-248 and huEpoR221-249 1H-15N HSQC spectra. Overlay of
huEpoR221-249 (red) and muEpoR220-248 spectra demonstrates a completely different HSQC
spectrum for the huEpoR221-249 as compared to the muEpoR220-248 spectrum. Underlined residues
represent sequence differences between mouse and human (all peak labels refer to mouse amino
acid assignments). Both peptides are at ~1 mM in 10 mM sodium phosphate, pH 7.0, 200 mM
DPC, 10% D2O (v:v). muEpoR220-248 was collected with ns=2, huEpoR221-249 with ns=2 on a 700
MHz spectrometer at 313 K.

What would the human dimerization interface look like if it were different than the
murine one? Figure 3.10 (panel A) shows helical wheel diagrams for the two EpoR TM
sequences. The muEpoR220-248 structure presented uses the dimer interface lined with Ser231,
Val235, Ser238, Thr242, and Ala245 (marked with asterisk). AUC experiments (65) and
TOXCAT experiments (19) indicate that the human sequence associates less strongly than the
mouse sequence. If the same helix interface is used in the human receptor, the replacement of
Ser238 with leucine in the human sequence may destabilize the helix dimer, assuming the polar
Ser238 sidechain contributes to dimerization. Alternatively, mutation of Ser238 to leucine may
force the use of a different interface. Leucine residues are not uncommon in TM helix dimer
interfaces, and are almost twice as common in the “d” position than the “a” position (142), so
why a leucine substitution at position 238 would be so destabilizing is unclear. If another
dimerization interface were to be used by the huEpoR, it is unclear what interface that would be.
However, maximizing the number of small or polar residues in the interface and restricting
leucine residues to the “d” position suggests that an interface ~52° counterclockwise (Leu235,
Leu242, Ser249; Ser232, Leu239, Ala246) might be used. This is the same interface described
for the murine TM dimer by Ruan et al. (64). Computational searches for low-energy symmetric
TM dimer interfaces suggest another possibility (Figure 3.10, Panel B). Comparison between the
symmetric dimers of the mouse and human sequences show that for both sequences, sidechains
of Thr242/243 form interhelical hydrogen bonds. However, the mutation of Ser238 in the
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muEpoR to leucine in the huEpoR forces a larger crossing angle in the human TMD (6° vs. 16°,
respectively). Interestingly, mutation of Leu239 to serine in the human TM sequence returns the
structure to a narrow crossing angle (7.5°) as seen in the mouse WT sequence model. The mouse
WT TM dimer energy is lower than that of the human WT TM dimer (-60.58 kcal/mol, -58.8
kcal/mol, respectively), which agrees with the difference in association seen using AUC
experiments (65). These data may also agree with other computational studies correlating the
packing density of different murine EpoR TMD-based sequences with cellular activity (77). In
that study, Thr242 was mutated to asparagine, glutamine and alanine, and Epo-induced receptor
activity increased with decreasing sidechain length (increased packing density,
Ala>WT>Asn>Gln). If decreased packing density of the EpoR TMD negatively affects receptor
activity, then the lower activity of the human receptor is explained by the larger crossing angle.

A.

*

B.
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Figure 3.10 muEpoR and huEpoR helix interfaces. A. muEpoR220-253 and huEpoR221-254
helical wheel diagrams. Left-handed coiled-coil (LHCC) helical wheel diagrams demonstrate
relative positions of the residues in the helix if the EpoR TM dimer is a LHCC. The murine and
human are positioned to be in the same register based upon the putative start of the TM helix (in
blue). The putative end is marked in red. An asterisk marks the TM dimer interface in the
muEpoR220-248 dimer structure. B. Computational modeling of mouse and human TM dimer
interfaces. Computational searches for low-energy symmetric TM dimer structures for the mouse
and human sequences result in interfaces with the same general interface, but with different
crossing angles (#). Mutation of Leu239 to serine in the human sequence recovers the narrow
crossing angle. The separation between the axes of the TM helices in the dimer (input
parameter) is fixed at 9.5 Å.
How could a change in the EpoR TM dimer crossing angle result in a difference in its
ability to be activated by gp55-P? While it has been shown that the ability of the gp55-P TMD to
interact is dependent upon a single serine residue in the TMD, the same study demonstrates that
gp55-P is able to activate the mouse TMD with S238 mutated to alanine (39), so S238 is unlikely
to be intimately involved in the interactions between the EpoR and gp55-P. This conclusion is
despite presentation in the same paper of an EpoR-gp55-P TM heterodimer model with Met390
from gp55-P and EpoR Ser238 in the interface of the heterodimer. The change in crossing angle
(&) in the EpoR TM homodimer (Figure 3.10) demonstrates a second, subtle consequence of
leucine at position 239 of the huEpoR TMD, namely a slight rotation of the TM helices with
respect to each other and a change in the interface of the EpoR TM dimer. Ser232 is clearly
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rotated to a position outside the interface; this rotation is reversed in the huEpoR L239S
mutation. This rotation in the huEpoR WT TMD may result in an obfuscation of the TM helix
dimer ‘outerface’ that would be available for interaction with gp55-P in the native EpoR TM
dimer structure. Therefore, if specific interactions between the EpoR and gp55-P TMDs are
disrupted by changes in the sequence of the TMDs, the disruption is likely the result of two
different changes. The first is a change in the relative homodimer’s (EpoR:EpoR or gp55P:gp55-P) ability to retain their native interfaces. Secondary to that is the inability to form
specific EpoR:gp55-P TMD interactions that are critical to TMD repositioning related to the
EpoR activation.

Helix Cap
The i+4 backbone hydrogen bonding network of #-helices contribute to the stability of
this particular type of secondary structure. An important and particularly interesting
characteristic of the #-helix has to do with the structural transition at the ends of the helix. At the
ends of the helix, the characteristic i carbonyl oxygen to i+4 amide proton hydrogen bonding
pattern is disrupted, leaving several unsatisfied hydrogen bonds. These bonds could be satisfied
by water, but a water NOESY experiment (98) demonstrates that these amide protons are not in
exchange with water (data not shown). If a hydrogen bond contributes -0.5 to -2.0 kcal/mol of
energy, then leaving 3 unsatisfied hydrogen bonds means an increase in the free energy of the
system of 1.5-6 kcal/mol per monomer (141). In order to minimize this energy increase, a
sequence dependent cap structure forms to stabilize the end of the helix (143). Typically, these
involve both polar and non-polar interactions. In an N-terminal cap, residues with a polar
sidechain forms a hydrogen bond with an amide nitrogen further C-terminal to the capping
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residue. Further stability comes from the packing of non-polar sidechains. This cap structure
successfully reduces the amount of free energy in the system, stabilizes the helix termini and
prevents helix unraveling.
Helix cap structures have been well studied and consensus sequences for both the Ctermini and N-termini caps have been determined (143). Unfortunately, a survey of the currently
available NMR solution structures of TM dimers (glycophorin A, T-cell receptor &&, EphA2, and
BNIP3), demonstrates none with a definitive helix cap structure (Table 3.3). This is in spite of
each of the sequences possessing a N-terminal capping motif sequence, as predicted by the
consensus sequences of Aurora and Rose (143). This begs the question as to whether the lack of
a cap structure is the result of a post-NMR data collection error (bias in structure calculation) or
a problem with everything leading up to the structure calculation input (NMR data collection,
data analysis or a problem with the system being studied). One possibility is that structure
calculation algorithms could be to blame; the necessary forcefields may not be ‘mature’ enough
to correctly handle correct structure calculation in the odd chemical environment at the
polar/nonpolar interface (membrane boundary). However, the consensus sequences for the
current cap motifs were in part determined through PDB structure searches. Given that these
structures were calculated with similar or identical forcefields, an error at this step is unlikely,
and we must search for other ways to explain the lack of defined helix caps in the structures
listed below.
Protein (PDB ID)

Sequence

Potential
Cap Motif

Glycophorin A

VQLAHHFSEPEITLIIFGVMAGVIGTILLISYGI

(1AFO)
*-

IIIb (F)

EphA2 (2K9Y)

EFQTLSPEGSGNLAVIGGVAVGVVLLLVLAGVGFFIHRRRK

Ia (V), Ib (I)

BNIP3 (2KA1)

GGIFSAEFLKVFLPSLLLSHLLAIGLGIYIGRRLT

Ia (L)

T-cell receptor &&

DSKLCYLLDGILFIYGVILTALFLRVKFSRSAD

Ia (L)

(2HAC)

Table 3.3 Potential helix caps in currently available PDB TM dimers. Several TM homodimer
structures are available for comparison. Each of these has a potential N-terminal cap sequence
motif, yet none of the structures demonstrate such a feature.

Interestingly, in examining our spectral data and the resulting calculated structure, an Nterminal helix cap is formed involving the sidechain of Asp224 and the amide proton of Leu226
(Figure 3.10). Furthermore, this cap is predicted from the protein sequence based on the Aurora
and Rose Ia (h-xpxhx) consensus sequence, where the first residue of the capping motif is
Leu223 and the N1 residue is Pro225. Statistically, proline is the most common residue at the N1
position for most of the N-terminus capping motifs (143). At the N3 position is Ile227, which
makes contacts with the N’ hydrophobic residue (Leu223). This structure is directed by our
through-space NMR data, Table 3.4 shows these contacts in the CN-NOESY spectrum. Specific
contacts are made between Asp224 and Ile227, Pro225 and Ile227/Leu228. The sidechain of
Asp224 seems to be within hydrogen bonding distance of the backbone amide NH groups of
Leu226. There are also contacts between Leu223 and Ile227, indicating that hydrophobic
packing contacts between the sidechains of these two residues contribute to the structure of the
cap. Interestingly, when Asp224 is mutated to cysteine, receptor processing and trafficking to the
membrane is affected, leading to about half the wild type receptor at the cell surface (75). The
receptor that does make it to the membrane is capable of binding Epo, but has a decreased level
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of activity. It is plausible that this decreased trafficking and activity is due to a disruption of the
local cap structure.
Spectrum
CN-NOESY

Contact
D222HN-S221C"/C#
D222HN-L226C#
L223HN-S221C#
L223HN-D222C#
L223HN-P225C"/Cd
L223HN-L226C"
D224HN-I227C"
D224HN-I227C$1/C$2/Cd
D224HN-L223C$
I227HN-L232C%
L228HN-P225C#
L228HN-I227C"/C$1/C$2
L228HN-S231C"
T229HN-P225C#/C"
T229HN-L223C$
T229HN-L226C#
T229HN-L230C$
T229HN-L232C%

Table 3.4 Helix cap contacts in NOESY datasets. Contacts defining the helix cap structure in
the muEpoR220-248 are listed. Contacts between residues S221-L232 are available to define the
structure.

Previous computational work by our group on the murine EpoR TMD indicated that a cap
structure forms between the sidechain OH of Thr229 and the amide proton of Leu232, one
helical turn lower than we see in our current NMR-based structure (74). The differences in the
two murine EpoR TM cap structures (Figures 3.11, 3.12) could have several different
explanations. First, the Kubatzky structure is the result of computational studies based upon only
two carbonyl chemical shifts (Leu228, Leu230). These chemical shifts were collected using
solid-state NMR methods from a peptide reconstituted into multilamellar lipid vesicles (DMPC).
Though counterintuitive, the DMPC bilayer has a shorter hydrophobic cross section (24 Å) than
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a DPC micelle (~30 Å) (144, 145). Therefore, a longer hydrophobic helix would be expected in
the DPC sample. It could be explained by the differences in surface curvature of DPC detergent
versus DMPC lipid. Detergent micelles have an inherent surface curvature that is greater than
that of the multilamellar lipid vesicles formed by the solid-state NMR preparation, which may
induce structural variations, especially at the helix termini. Perhaps the greatest drawback of the
solid-state based structure is that this structure was calculated based upon only two carbonyl
chemical shift constraints resulting from solid-state NMR studies in lipid bilayers. In contrast,
the solution NMR cap structure is the result of multiple through space contacts and measurement
of chemical shifts of all relevant atoms.

T229
L230
L228
1.2 Å

L232

Figure 3.11 Previous muEpoR dimer helix cap structure. Helix cap structure from Kubatzky et
al. (74) indicating that the sidechain OH of T229 forms a hydrogen bond with the HN of L232.
The sidechains of L228 and L232 form hydrophobic contacts.
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D224

L223
1.9 Å
I227
L226

Figure 3.12 Current muEpoR dimer helix cap structure. Helix cap structure demonstrates
D224 sidechain capping the helix by forming hydrogen bonds with the NH of L226. The
sidechain of L223 makes contacts with the sidechain of I227.
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Chapter 4-Structural Changes in the Erythropoietin Receptor Upon Activation
To begin to answer the question of how the TMD is involved in the function of the EpoR,
we extend the sequence of the construct to include the conserved intracellular Box 1 region. Also
added are several amino acid at the N-terminus to capture a larger portion of the EC-JM region, a
part of the receptor which captures a number of positions that modulate receptor activity when
mutated to cysteine. Figure 4.1 depicts the sequence of the muEpoR218-268 peptide and the regions
of the receptor added (red text) for these studies. The underlined are those residues that, when
mutated to cysteine (Leu223, Leu228) modulate receptor activity (74, 75).

Figure 4.1 Amino acid sequence of the recombinant muEpoR218-268 peptide. The murine EpoR
TM Box 1 construct includes 20 residues of the ICD corresponding to the region including the
Jak2 binding Box 1 region (PGIPSP). Underlined are residues that, when mutated to cysteine,
modulate receptor activity. Also included are the residues of the switch region (L253, I257,
W258) demonstrated to be important for Jak2 activation.

This construct retains the hydrophobic TMD and adds three residues to the N-terminus
(LTA). This N-terminal extension represents most of the remainder of the sequence between the
WSXWS motif in the D2 domain and the TMD. Added to the C-terminus are 20 residues that
represent the “switch” region and the Jak2 binding site, Box 1. The addition of this intracellular
region serves two purposes. First, it would allow interaction studies between the Jak2 FERM
domain and this longer EpoR TM containing peptide, as the Box 1 region is demonstrated to be
necessary for association of these Jak2 with the EpoR (46, 146). More importantly, it allows the
assessment of intracellular structural changes upon the simulation of the active state. Two
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methods of simulating the active state are specific cysteine mutagenesis or the addition of the
gp55-P TM peptide, which activates the EpoR (38). Therefore, the addition of more of the
protein sequence surrounding the TMD adds functional relevance and context for examining the
propagation of structural changes to the ICD upon activation.
Cysteine Mutants
Two important cysteine mutagenesis studies have been performed on the EpoR TMD and
surrounding regions (74, 75). The difference between the two studies is the method of
crosslinking, passive in Lu et al. (75) versus active with the lipid soluble linker orthophenylenedimaleimide (o-PDM) in Kubatzky et al. (74). Both studies identified L223C as a
constitutively active mutant. L226C and I227C were also identified to be constitutively active,
but at a lower level than L223C. D222C, P225C and L228C are not constitutively active, but can
respond to Epo (wild-type like), though P225C responds at lower levels. D224C is an interesting
case, as it is expressed at the cell surface at reduced levels (~50%), and is not processed through
the Golgi (endo-H negative). It shows a very small amount of constitutive activity, but cannot
respond to WT levels when exposed to Epo.
The Kubatzky study (74) differs from the Lu et al. (75) study because of the advantage of
being able to actively crosslink cysteines inside the TMD, using the membrane-permeable
crosslinker o-PDM, where disulfides normally do not form. Interestingly, crosslinked receptor is
found with L241C, L244C, and A245C. However, these receptors are not constitutively active,
though oddly both Leu241 and Leu244 are in the “active” interface described in Seubert et al.
(76). Recombinant L223C and L228C muEpoR218-268 are used in this study to approximate the
active and the WT-like receptor, respectively.
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Wild-Type muEpoR218-268
Figure 4.2 shows the 1H-15N-HSQC spectrum of the muEpoR218-268 construct in DPC
detergent micelles. This spectrum has more peaks than the muEpoR220-248 spectrum (Figure 3.2),
reflecting the extra residues added to the construct sequence. Peaks for residues in the TMD are
generally of lower intensity, reflecting an overall lower mobility of this region than the N- and
C-termini. Despite the added molecular weight, the spectrum peaks are generally well resolved,
indicating that the preparation is homogenous. Significant peak overlap exists between the
muEpoR218-268 and the muEpoR220-248, indicating that the TM conformation is preserved in the
larger construct (Figure 4.3). Chemical shift deviation ('%) is calculated for each peak using the
formula:

where CSH1/CSN1 and CSH2/CSN2 are the chemical shifts of the relevant hydrogen and nitrogen in
the first spectrum minus the second spectrum (147). Most of the intermonomer residues
identified by the TMD structure (Ser231, Val235, Ser238, Thr242) are in the same position in the
muEpoR218-268 spectrum. The only intermonomer peak that is not in the same position is Ala245.
It is likely shifted because the entire C-terminus is shifted due to the additional C-terminus
residues. Full 3D assignment reveals that all amino acids can be assigned with the exception of
Leu226 and Arg251. Thr252 has very low intensity, and Arg250 is buried in the more intense
Leu223 resonance, but can be assigned by examining the 3D experiment strips. The low intensity
of these peaks is likely due to flexibility at the intracellular membrane boundary. At this site,
where the TM helix emerges from the detergent micelle and transitions from #-helical to random
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coil, structural heterogeneity is not unsurprising. It is unclear if the structural heterogeneity is an
integral part of the system or a result of the study methodology.

Figure 4.2 The murine EpoR WT TM Box 1 1H-15N-HSQC spectrum. The spectrum for
muEpoR218-268 shows good resolution given the size of the detergent-protein complex. Peak
assignments are shown on the spectrum; only 2 amino acids remain unassigned (L226, R251).
Spectrum was collected on a Bruker 700 MHz spectrometer at 313 K, with 32 scans. Sample is
~1 mM protein, 10 mM sodium phosphate, pH 7.0, 200 mM d38-DPC, 10% D2O (v:v).
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Figure 4.3 Overlay of muEpoR220-248 1H-15N-HSQC on muEpoR218-268 1H-15N-HSQC. Only five
of the resonances in the transmembrane region (L244-S248) shift when the peptide is lengthened
to muEpoR218-268 (only S221-S248 are labeled). Residues in the TMD are numbered, numbers in
blue represent a significant peak shift (and peaks for each construct are labeled). Generally
these shifts occur in the last turn of the helix (A245-S248). Sample is ~1 mM protein, 10 mM
sodium phosphate, pH 7.0, 200 mM d38-DPC, 10% D2O (v:v).
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Figure 4.4 Chemical shift
differences of the TM domain
between muEpoR220-248 and
muEpoR218-268. The core
residues of the TM domain,
including the dimer interface
residues S231, V235, S238,
and T242 remain in the same
position, an indication of
conformation preservation.

Simulating the Active State: L223C and gp55-P
In order to begin probing the functional mechanism for the EpoR, spectra of the WT
(inactive) and the active state were compared. Peptides of the muEpoR218-268 with the L223C
mutation were expressed, purified, and reconstituted into DPC micelles. Some optimization was
necessary to obtain high quality spectra. First, DTT (20 mM final concentration) was added to a
dilute (~2 ml) sample, and then the sample was dialyzed versus 3 changes of 10 mM sodium
phosphate, pH 7.0 (1 kDa MWCO). This prevents TM dimers from two micelles from
crosslinking, which degrades spectral quality because of slower molecular tumbling. Then the
sample was concentrated to 250 uL and loaded into the Shigemi NMR tube. Other than these
deviations, the NMR samples were prepared in the same manner as the WT TM peptides.
The L223C muEpoR218-268 spectrum-WT spectrum comparison is shown in Figure 4.5. It
is clear from the spectral comparison that there are few shifted peaks from the WT spectrum, an
indication that the structures are comparable. As expected, peaks in the vicinity of L223C were
shifted quite dramatically (Asp222, Asp224), likely due to perturbation to the local structure.
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Chemical shift deviation calculation of the region from Ile227-Phe268 (Figure 4.6) shows that
outside of the residues immediately surrounding L223C, His249 shifts the most of all residues,
followed by Gly260 and Leu253. These results indicate that a mutation in the extracellular
region can effect a change in the intracellular region of the protein. The significance of the large
shift in Ile227 is thought to be due to local disruption of the helix cap structure, where the side
chain of Asp224 hydrogen bonds to the NH of Ile227.

Figure 4.5 1H-15N-HSQC comparison, L223C (red) compared to WT (black). The 1H-15NHSQC of the L223C muEpoR218-268 was prepared as described and a spectrum was collected at
313 K with 32 scans. The overlay demonstrates that while many peaks overlap, several do not.
Red text denotes new peaks/peak positions for the L223C mutant. H249, L253, and G260 are in
blue. Sample is ~1 mM protein, 10 mM sodium phosphate, pH 7.0, 200 mM d38-DPC, 10% D2O
(v:v).
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Figure 4.6 1H-15N HSQC chemical shift differences, active compared to wild type. Chemical
shift differences from the WT spectrum are calculated for the peaks in 1H-15N-HSQC for each
active sample, using the formula in the text. Differences from WT are blue:L223C, red:gp55-P.

gp55-P
Recombinant gp55-P349-409 was expressed as a His-MBP fusion protein without isotopic
labels and purified using the same method as the His-MBP EpoR TM fusion proteins (Chapter
2). Purified TM peptide was mixed 1:1 (molar ratio) with 15N labeled muEpoR218-268 and
reconstituted into DPC micelles. The resulting 1H-15N-HSQC spectrum, when overlaid with the
EpoR WT spectrum, demonstrates that many peaks are in the same position indicating that the
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overall structure is the same (Figure 4.7). However, shifts of the same magnitude and direction
are seen in His249, Leu253, and Gly260 (Figure 4.6) as were seen in the L223C mutant.

Figure 4.7 1H-15N-HSQC comparison, WT compared to WT + gp55-P. Wild type muEpoR218-268
+ gp55-P was prepared with an EpoR:gp55-P molar ratio of 1:1. The spectra were collected on
a 700 MHz spectrometer at 313 K with 32 scans. The overlay demonstrates that while many
peaks overlap, there are several that do not, including H249. black=WT, red=WT+gp55-P.
Sample is ~1 mM, 10 mM sodium phosphate, pH 7.0, 200 mM d38-DPC, 10% D2O (v:v).
Residues that shift significantly are indicated with blue text.
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The Inactive State: L228C = Wild Type
As mentioned in previous sections, the assumption is made that in this system, the WT
sequence represents the inactive state of the EpoR. This assumption is necessary in order to
establish a baseline for our structural studies, but must be confirmed experimentally if WT
spectrum comparisons are to be made with active structures. This is accomplished using the
L228C mutant. The mutant is demonstrated not to be constitutively active, but responds to Epo at
the same level as wild type (74, 75), therefore it resembles the wild-type receptor in the absence
of ligand. When this construct is prepared in the same manner as the L223C sample, peak shifts
are seen in the residues surrounding the inserted cysteine as expected (Figure 4.8). However, the
residues that shifted in both the L223C mutant and the WT + gp55-P spectra, notably His249 and
Leu253 remain unshifted, and while Gly260 is the peak that shifts most in the spectrum, the
magnitude of the shift is less than both active spectra (Figure 4.9). This result indicates that
His249 and Leu253 are markers of the active state.

+'

Figure 4.8 1H-15N HSQC comparison, WT compared to L228C. L228C muEpoR218-268 was
prepared as described and a spectrum was collected on a 700 MHz spectrometer at 313 K with
32 scans. The overlay demonstrates that while many peaks overlap, a few do not. H249, L253,
and G260 are shown in blue. Black=WT, red=L228C. Sample is ~1 mM, 10 mM sodium
phosphate, pH 7.0, 200 mM d38-DPC, 10% D2O (v:v).
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Figure 4.9 1H-15N-HSQC chemical shift differences, inactive compared to wild type. Chemical
shift differences from the WT spectrum are calculated for the peaks in the L228C 1H-15N HSQC,
using the formula in the text.

Structural Changes Between Inactive and Active Constructs
Engineered cysteine mutations are expected to cause local changes in protein structure
and therefore the 1H-15N-HSQC spectrum due to changes in the local environment of
surrounding nuclei, as we see with the residues surrounding L223C and L228C. However,
spectral shifts of more distant amino acids (e.g., the opposite end of the helix) are interpreted as a
structural change associated with activation.
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His249
His249 is seen to shift in the same direction in the same magnitude in both the L223C
and the WT+gp55-P spectra (Figure 4.10, B/C). This result, coupled with the lack of movement
in the L228C spectrum (Figure 4.10, A), suggests that His249 is a marker of the active state.
There are two pieces of data in the literature regarding His249. First, in an EpoR-PrlR chimera
study (73), one of the receptor constructs used was a double mutant (L223V, H249G),
presumably to insert restriction cloning sites for connection of chimeric receptor pieces. This
L223V/H249G mutant appeared to be wild type like; without constitutive activity, but could
respond to Epo at the same level as the WT receptor, as measured by GFP fluorescence, a
measure of cell proliferation. The second piece of data also comes from Constantinescu, an
alanine mutagenesis study of the intracellular juxtamembrane region (72). In one mutant,
His249, Arg250, and Arg251 are mutated to alanine; this construct retains much of its wild-type
level of activity, as measured by cell proliferation assays.
These points argue against His249 being intimately involved in the activation
mechanism. However, this is only one possible extrapolation of our data to a potential
mechanism. While chemical shift deviation would be expected if His249 were important for
activation, shifts would also be expected if His249 were influenced by a change in local structure
that depended upon transition to the active state. For example, if His249 were pulled into the
membrane bilayer a change in chemical shift would be expected, as would one if a change in
secondary structure occurred. In this way, the NMR data and the cell biological data are not
incongruent.
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A.

Figure 4.10 Position of H249 is
affected by active/inactive
structures. Overlays of the inset
regions of inactive and active
spectra showing the area
surrounding H249 demonstrate
that H249 shifts in the active
L223C and EpoR+gp55-P
spectra, but not the L228C wild
type-like spectrum. H249 and
L253 are shown in blue. A) WT
(black) vs. L228C (red) B) WT
(black) vs. L223C (red) C) WT
(black) vs. EpoR+gp55-P (red).
Sample is ~1 mM, 10 mM
sodium phosphate, pH 7.0, 200
mM d38-DPC, 10% D2O (v:v).

B.

C.
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Leu253
In the active structures, Leu253 NH shows chemical shift deviation from the WT
spectrum. Three conserved residues (Leu253, Ile257, Trp258) have been shown, through
mutational studies, to be absolutely required for receptor activity (72, 76). These residues
constitute a hydrophobic motif that in addition to being highly conserved across species for the
EpoR (Figure 1.4), they are relatively conserved among the Group 1 cytokine receptors (Figure
1.2, and (72)). Despite conservation, the importance of the positioning of these residues is
unclear. The position of these residues relative to the Box 1 motif is preserved across cytokine
receptors, but not with respect to the end of the TMD (Figure 1.2). This would seem to indicate
that whatever function they perform, they act in concert with the Box 1 motif and independently
of the TMD. However, this is not necessarily true, because the function of the TMD in the rest of
the cytokine receptors is unclear. If the TMD in the GHR and the PrlR drive dimerization as they
do in the EpoR (73) and the TpoR (15), then two pieces of information are still missing. First, the
putative dimerization interface in these receptors is unknown-the relative position of the threeresidue motif could indeed be consistent with that of the EpoR. Second, the conformation of the
residues linking the TMD and the L, I, W residues is unknown. Much research still needs to be
performed on this interesting region before cytokine receptor activation is understood.
Chemical shift index analysis (148) and dihedral angle predictions for the wild type and
L223C muEpoR218-268 samples indicate that both are #-helical from Pro225-Ile257 (Figure 4.11).
However, it is important to note that intensity is lost for Arg250-Arg251 in the 1H-15N-HSQC,
which would indicate flexibility or structural heterogeneity of this region. Interestingly, if the ICJM is a rigid #-helix, then the hydrogen bonding partner for Leu253 would be the carbonyl of
His249, the chemical shift of which is unclear at the moment in the wild type sample-there are
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two possible chemical shift assignments, 175.8 ppm or 173.3 ppm. The L223C active carbonyl
chemical shift of His249 is 176.05 ppm, which is predicted to be helical. Because the chemical
shift of the wild type sample is upfield of the L223C sample, it is possible that there is a
difference of secondary structure in this region between the two samples. However, because of
the uncertainty of the exact chemical shift of the wild type sample, further investigation is
required.

Figure 4.11 Chemical shift index and secondary structure, muEpoR218-268 wild type and
L223C. Chemical shift index is calculated on C!, C" and C=O chemical shifts between the WT
and L223C samples. Secondary structure prediction is a result of these calculations and dihedral
angle predictions. A) Wild Type B) L223C.
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Box 1
Little is known about this region with the exception that it is necessary for Jak binding.
This nine residue, proline-rich motif is highly conserved across species (for the EpoR) and
somewhat conserved across receptor classes (Figure 1.2). With the possible exception of Gly260,
this study was unable to detect any changes in the structure of the Box 1 region upon activation
(L223C or gp55-P). The likely explanation is that because this region normally binds Jak2,
whatever the structural conformation adopted in the TM-JM constructs in the absence of Jak2
may be irrelevant.
Cysteine Mutants and Protein Structure
Cysteine mutagenesis is an important tool in protein biochemistry, used to modulate a
protein’s state of activity, but is a tool of somewhat dubious value. Cysteine residues do not
normally oxidize to form disulfides in the hydrophobic membrane environment, so structural
effects of cysteine mutagenesis are unknown. While the data herein are presented without
explicitly stating that the L223C construct is a disulfide-linked dimer, it is important to disclose
that chemical shift analysis of the C" of Cys223 indicates that it is unlikely to be oxidized. 1H15

N-HSQC studies were performed on a copper-phenanthroline crosslinked L223C and

crosslinking was confirmed by SDS-PAGE. However, with the exception of the residues in the
region of the copper-phenanthroline (lost due to paramagnetic effects), the non-actively
crosslinked spectrum was the same as the copper-phenanthroline crosslinked spectrum (data not
shown). Therefore, whatever structural changes are induced by the L223C mutation is
independent of disulfide crosslinking. Indeed, in Lu et al.’s cysteine mutagenesis study (75),
only a fraction of the L223C receptor exists as a crosslinked dimer. The strong effect of cysteine
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without disulfide linking, while surprising, is not without explanation, as this region is part of a
helix cap motif that is sequence dependent (Chapter 3).
Helix Cap
While we lack the datasets necessary for constructing a high resolution model of the Nterminal helix cap region for the muEpoR218-268 WT and L223C proteins, the dihedral angles
predicted from the chemical shifts of backbone atoms can be used to create a model. While the
same helix cap contacts are made in both the WT and the L223C structures as in the muEpoR220248

structure (Chapter 3), the replacement of Leu with Cys at position 223 causes a coiling of the

remainder of the N-terminus (Figure 4.12 A, B) compared with WT, which seems to be fully
extended. The significance of this is at the moment unknown. However, considering the rigid
coupling that is required for an ECD structural change to be transmitted through the TMD to the
ICD, even small changes can have a significant impact on structure, and therefore activity. This
is even more important given that the region between the WSXWS motif and the helix cap
contains only 10 amino acids.
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A.

B.

Figure 4.12 Helix cap models, WT & L223C. Helix cap models were constructed based upon
dihedral angles calculated from the chemical shift values of backbone atoms. Green=WT,
Blue=L223C. Cysteine at position 223 causes a significant change in structure of the Nterminus, as the A) side view (stereo), L218-S231 B) view from N-terminus (stereo), L218-S231.
Activation Mechanism
The NMR measurements made on the wild type, L223C and the wild-type + gp55-P
reveal several details about receptor activation. First, the fact that the spectral shifts between the
inactive and the active structures are unlikely to be due to a rotation of the two helices and
formation of a new interface, as proposed by Seubert et al. (76). In fact, the residues
demonstrated to be lining the interface by intermonomer NMR measurements show very
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minimal shifts. Second, several key juxtamembrane residues are perturbed during activation.
Third, while the results of activation with L223C or gp55-P are essentially the same (His249
movement et al.), structural changes in the TMD between L223C and gp55-P are different.
L223C induces structural changes at the N-terminus that cause or allow TMD movement to an
activating position. Gp55-P causes the same activating changes in the C-terminus as L223C, but
does not perturb the structure of the N-terminus. This is an indication that the interaction
between gp55-P and the EpoR forcibly repositions the TMD into the active conformation. It is
strange that greater shifts are not seen in the TMD residues of the EpoR upon gp55-P binding,
but the average shift over the length of the TMD is greater for gp55-P than for L223C. This
disparity indicates that while the L223C mutation works by changing the N-terminus structure to
reposition the interfacial residues in order to move the C-terminus, gp55-P may work from the
outside (helix ‘outerface’) to accomplish the same task.
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Chapter 5-Models for Erythropoietin Receptor Activation
Chapters 3 and 4 present the first atomic resolution studies of the EpoR TMD. An
important aspect of these studies is that the TM domain is first shown to be dimeric under the
conditions used and then measurements are made using a high resolution approach, namely
NMR spectroscopy. Previous reports studying the TMD of the EpoR are unable to definitively
say that the EpoR TM system under study is dimeric. This shortcoming leads to conclusions that
overstate the data. In other studies, if a dimer could be demonstrated (e.g., with AUC), then the
resolution to determine an actual dimer interface was missing. What makes the studies described
here all the more important is that the dimeric nature of the system under study is demonstrated,
and that the system is probed with angstrom resolution.
TM Helix Association/Interactions
Several sequence motifs for helix association have been identified. Perhaps the best
studied is the GxxxG motif. This motif is the basis for TM dimerization of glycophorin A (125)
and BNIP3 (149), among other TM dimers. The two glycine residues in this motif allow the
close approach of the helices within the dimer, while amino acids distal but on the same face
modulate the strength of the TM interaction (150). The leucine zipper is another dimerization
motif (62). Present in the DNA binding transcription factor GCN4, the hydrophobic residues
(Leu/Val) form the hydrophobic dimer interface (63), while charged or polar residues form the
surface that is exposed to water. However, it is unclear if homodimeric TM proteins make use of
the strict leucine zipper as well. Despite TOXCAT studies on TM proteins possessing a similar
sequence motif as GCN4 indicating variable propensities for self-assembly (61), studies by the
developer of the TOXCAT assay indicated that model leucine zipper peptides containing Val at
the “a” position did not self-associate, and a polar residue was required for the peptide to do so
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(139). Further work on the EpoR TMD defined a slightly different interface with serines at the
“a” positions (64). Such a motif may more appropriately be characterized as a serine zipper,
which has been defined in model TM peptides (151). However, the asparagine mutagenesis
studies by Ruan et al. (64) may be misleading, as the interface results may be due to trimer or
oligomer formation. Studies by Zhou et al. (139) and Choma et al. (138) have determined that
Asn-containing peptides can form trimers that cause abnormally intense results in the TOXCAT
assay. These strong results can mislead researchers into believing that a particular Asn mutation
causes “strong” dimerization. Therefore, while TOXCAT studies can be a useful tool to define
whether TM segments self-associate, caution must be exercised when interpreting results from
such studies as dimers, especially when it is the only method used to assess association. The
implication for EpoR signaling is that the dimerization interface defined by Ruan et al. (64) may
not be the actual dimer interface. NMR measurements made on muEpoR220-248 indicate that
Ser231, Ser238 and Thr242 line the dimer interface, with Val235 and Ala245 allowing close
approximation of the two helices. This interface has support in the literature from Put3-EpoR
fusion studies in which only constructs with this interface are activated by gp55-P (76).
EpoR TM Helix Movement During Activation
Several general models have been proposed for the function of proteins that associate via
their TMDs. The three possibilities include a rigid turning of the TMDs relative to each other
(15), a change in the helix crossing angles relative to each other (scissoring) (152), or a
longitudinal motion of one or both of the TMDs in the lipid bilayer (pistoning) (153). It is
important to note that regardless of mechanism, there appears to be rigid coupling of the TMD
and the ICD. Put3-EpoR TM fusion experiments demonstrate that receptor activity has a
dependence on the rotational orientation of the TMD (76). Insertion of alanine residues between
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the TMD and the intracellular “switch” region of the EpoR also modulates receptor activity (72),
with 1-2 inserted alanines reducing activity and 3 inserted alanines (~1 helix turn) recovering
wild type activity. This result, coupled with the Put3-EpoR fusion data, suggested that the helix
continues after His249 and that the position of the ICDs, and by extension receptor activity,
depends upon TMD rotational orientation. This hypothesis fit nicely with the ECD crystal
structures that demonstrated rotation of the two ECD halves upon ligand binding (8).
The TM rotation model for activation also has support from a related receptor family, the
ErbB receptors. For example, cysteine mutagenesis studies have demonstrated that EGF receptor
kinase activity is coupled to the rotational orientation of the TMD (154). The kinase domain of
the Neu receptor, a related RTK, was also shown to have activity that is coupled to the rotational
orientation of the TM region, albeit with a model TM sequence instead of the actual Neu
receptor sequence (155). The receptor for atrial natriuretic peptide (NPRA) also seems to have a
similar rotational mechanism of activation (156).
The bacterial aspartate chemoreceptor TAR is a good example of the piston model of
signaling. This TM receptor is a homodimer, but the functional unit is thought to be a trimer of
dimers. Tryptophan residues flank the TMD sequence, but activity seems to be controlled by the
Trp at the C-terminus of the TMD, which is followed by a tyrosine. When the Trp-Tyr motif is
moved closer to the N-terminus of the helix, the kinase is inactive (153). The opposite occurs
when the Trp-Tyr motif is moved further C-terminal. The transitions along the bilayer normal are
small, ~1.5 Å, which is accompanied by a small change in helix tilt (~5°) (153).
While the NMR data presented here for the muEpoR218-268 do not necessarily disagree
with a rigid coupling of the TMD and the ICD, it is incompatible with a TM rotation model. The
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NMR spectra of the muEpoR220-248 and muEpoR218-268 are those of a symmetric molecule where
the TMDs do not change conformation greatly when switching from the inactive (WT) to active
(L223C, gp55-P) conformations. A change in the TM dimer interface would be expected to cause
shifts in the residues that were part of the old (inactive) interface, as well as shifts in residues in
the new interface. Therefore, the NMR measurements presented here appear to be more
consistent with a helix tilting model or a piston model.
Implications for Other Group 1 Cytokine Receptors
It was hoped that the specific interaction of the TMDs of EpoR would provide a model
for the function of other cytokine receptors, especially the members of the Group 1 receptors
(GHR, PrlR, TpoR). However, it seems that even between members of this subgroup there may
be divergent function. The GHR has the fewest polar residues in the putative TMD of all Group
1 cytokine receptors (Figure 1.2), and no other immediately discernable dimerization motif.
TOXCAT assays performed as controls for self-assembly of the EpoR TM domain indicate that
the GHR TMD has no propensity to self assemble (19). This correlates well with the receptor
monomer association studies performed on chimeric GH receptors harboring the LDLR TMD
(13). The results of these studies indicate that the EC domain, not the TMD, mediates receptor
self-assembly. Furthermore, comparisons between the ECD crystal structures of the EpoR and
GHR reveal that the GHR has more inter-D2 domain contacts than does the EpoR (45).
Together, these observations indicate that although the inactive and active forms of the cytokine
receptor are dimeric, the mechanism of dimerization may differ between receptors.
The TpoR is divergent as well. It possesses a duplicated ECD, not uncommon in the
cytokine receptor family. However, when this extra ECD is deleted, it causes constitutive
receptor activation (157). There is also an additional five-residue insert (R/KWQFP) that
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regulates activity of the TpoR (158). Deletion of this insert causes constitutive receptor
activation. There are also several clinically relevant mutations of the TMD (S505N) or
surrounding regions (T487A, W515K/L) that cause receptor hyperactivity, while for the EpoR
none are known. Given these structural and functional differences between the Epo and the other
Group 1 receptors, while they seem to generally function similarly, it seems likely that each
receptor has evolved receptor-specific mechanisms for precise control of activation and cell
signaling. These are likely related to pathway importance, cellular receptor density, and
concentration and affinity for ligand.
Implications for the Activation Mechanism of EpoR
While there is evidence for a rigid coupling of the TM-ICD functions, there is almost no
data on the relationship between the ECD and the TMD and how information is transmitted
between the two. The crystal structures of the ECD with and without ligand include several of
the residues between these two regions, but the structure is undefined. The only constitutive
mutant is the R129C mutation, which crosslinks the two D2 domains of the ECD (32). In the
crystal structure of the Epo-bound ECD (PDB ID:1CN4) these residues are more than 30 Å
apart. Positioning the D2 domains of receptor monomers so the R129C residues are within
disulfide bonding distance would also reposition the EC-JM region to be in close proximity. If
the constitutive activity of the L223C mutant depends upon disulfide linkage, then it would seem
to accomplish the same thing. A recently described activating mutation of the TpoR (T487A) is
located in this same region of the receptor (34). Recent studies on the Prl receptor where one to
four alanine residues were inserted between the ECD and the TMD indicated that ligand-induced
activity did not suffer (17). It is clear that ligand binding to the ECD of cytokine receptors causes
structural changes that are propagated through the TMD to the ICD, but how remains a mystery.
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Box 1, Jak2 and Prolines
Chemical shift analysis and dynamic NMR studies indicate that the rigid helical nature of
the EpoR TM and IC-JM region is encoded by the sequence of the receptor (up to Ile257), but Cterminal to that the structure is unknown. The conformations of the WT and the L223C Box 1
regions seem to be generally very similar as judged by the 1H-15N-HSQC (Figure 4.5). These
studies lack the ability to determine the conformation of the Box 1 region that binds Jak2. It may
be that the conformation of the Box 1 region in the absence of Jak2 is irrelevant, as there is
evidence that the EpoR (46) and TpoR (47) require Jak2 to be properly processed through the
Golgi and transported to the membrane.
It is interesting to speculate about the role of the proline-rich Box 1 region and activation
of the cytokine receptors. The proline residues in Box 1 throughout the cytokine receptor family
are highly conserved, but their function is unknown. Given proline’s ability to be in the cis or
trans conformation, it seems like a natural point of pathway regulation. Indeed, others have
investigated peptidyl-prolyl isomerase (PPIase) activity in regulating other signaling pathways
(159), and the processing of amyloid precursor protein (160). Pin1 is a PPIase that recognizes
Ser/Thr-Pro motifs (161). Given the presence of the Ser263-Pro264 sequence, this is a potential
target for regulation. A biophysical study of a peptide homologous to the sequence of the PrlR
Box 1 region (IFPPVPGP) indicates that it is very flexible, but has a definite preference for cisor trans-conformations in water (trans-trans-cis-trans) (162). The first, third and fourth Pro are
conserved between the EpoR and PrlR (Figure 1.2). The chemical shift of the C" resonance is
sensitive to cis/trans isomerization, the chemical shifts of C" for Pro259, Pro262, and Pro264 for
both wild type and L223C EpoR are all more consistent with a cis conformation. This is unusual,
as the cis conformation is expected to be found only ~10% of the time (163). The significance of
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this is unclear, but given that our peptides were expressed in bacteria, it is possible that
processing is different from mammalian expression systems. It is also possible that the C"
chemical shifts observed are unrelated to the isomer present and are otherwise affected by the
environment of the peptide.
Mechanism of Activation
To postulate a mechanism for receptor activation, I begin with two premises: 1) that the
EpoR dimers are pre-formed, and 2) that the TMD mediates receptor dimerization. The structure
of the unliganded ECD dimer (9) leaves the C-terminal residues too far apart (~78 Å) to connect
to a TM dimer, the TMDs would have to be monomeric. Because these two data points are
incompatible, and several lines of evidence suggest that the TMD mediates dimerization of the
EpoR in cells (73), the unliganded ECD structure is unlikely to be correct. Interestingly, the
structure of the TM dimer presented here and the ligand-bound ECD structure (PDB ID:1CN4)
are compatible, the C-terminus of the ECD and the N-terminus of muEpoR220-248 are separated
by about the same distance and can be linked without difficulty (Figure 5.1). This exercise does
not immediately suggest any clues as to how Epo binding changes in the ECD are propagated
through the EC-JM domain to the TMD.
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Figure 5.1 Human EpoR ECD linked to mouse TMD. The human EpoR ECD dimer with
bound-ligand (Pro7-Thr220, PDB ID:1CN4) is joined to the mouse EpoR TM dimer (Ala221Ser248). Pro225, Ser231, Ser238, and Thr242 sidechains are shown for each monomer.
Membrane boundaries are shown as horizontal lines.

Studies on the region that connects the TMD and the Box 1 motif indicate that Ser248Ile257 is a continuous helix (72). The NMR measurements on the wild type and the L223C
sequence (Chapter 4) suggest that this may be the case in the muEpoR218-268 structure. Some
controversy exists with regard to how activation is transmitted through the TM dimer of cytokine
receptors. Studies on the EpoR indicate that receptor activity may be linked to the rotational
orientation of the TMD (72). However, similar studies on the PrlR indicate that its activation is
not consistent with rotation or a piston motion of the TMDs (17). The NMR measurements
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presented here on the muEpoR218-268 peptide are inconsistent with a rotation model. The 1H-15N
HSQC spectra of the L223C and the wild type EpoR + gp55-P show considerable overlap with
the wild type spectrum, an indication that the overall structure does not differ greatly between the
wild type and the active conformations. If the L223C and the wild type EpoR + gp55-P spectra
are truly the result of studying the active conformations, then the only models that would be
consistent with the structural data are a helix tilting model or a piston model where both helices
move in or out of the membrane simultaneously. With respect to the helix tilting model, two
modes of tilting are possible, one where the helix crossing angle changes (Figure 5.1, A), or one
where the interhelical distance becomes unequal (i.e., greater at the bottom than the top, Figure
5.2, B). For these two models, small changes in relative helix tilt should result in a significant
change in intracellular distance. The residues from His249-Ile257 would constitute an additional
length of ~13.5 Å, if it is a continuous alpha helix. If the crossing angle were centered in the
middle of the TM segment (~17 Å), then the horizontal displacement of the two helix C-termini
would be 5.4 Å, assuming a 5° tilt with the bilayer normal (sin 5° = X/30.5 Å). This is additive to
the interhelical separation that already exists. The other possibility is that the entire peptide
dimer piston model where the entire complex moves in or out of the membrane, parallel to the
bilayer normal (Figure 5.2, C). How this would activate the intracellular kinases is not clear,
unless the act of physically changing the distance of the kinase from the bilayer causes an
activating (or inactivating) conformational change. Because distance measurements have not
been made for the larger muEpoR218-268 peptide, the precise interface and thus the activation
mechanism remains unknown.
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Figure 5.2 Possible activation mechanisms. Potential activation mechanisms consistent with the
NMR measurements presented here. A) Helix tilting repositions the C-terminal ends of the
helices with respect to each other. B) Second helix tilt mechanism allows relative repositioning
of the C-termini in a different manner. C) A piston model where the interface remains the same
in the inactive and the active structures.

For the intracellular side, changes that occur upon whatever conformational change the
TMD undergoes are also unknown. This is even more of a mystery because no structure of the
ICD exists. It is known that the FERM domain of Jak2 binds to the proline-rich Box 1 sequence,
but the relative positions of the FERM and the kinase from the two receptor chains are unknown.
The NMR measurements made here of the Box 1 region are consistent with a random coil
geometry. Therefore, it is not clear if the Box 1 region has a defined structure in the absence of
Jak2. However, the structure of the ICD may not be as important as the state of Jak2 residence on
the receptor ICD.
Funakoshi-Tago et al. (164) have demonstrated with mutants of Jak2 that
phosphorylation of Tyr119 after receptor activation triggers Jak2 dissociation from Box 1. This
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fits with another observation about the EpoR that suggests a dissociation of Jak2 from Box 1, the
ubiquitination of Lys256 (48) in response to Epo-induced activation and subsequent degradation
of the EpoR (49). Lys256 is a residue in the switch region, only one amino acid away from the
beginning of the Box 1 sequence, where Jak2 binds. If Jak2 remained bound to Box 1 after Epoinduced activation, then it seems unlikely that a rapid ubiquitination event could occur, as this
would require space for the binding of ubiquitin and the ubiquitination machinery. More recent
experiments on the GHR demonstrate a similar detachment of Jak2 upon receptor activation
(165). Therefore, the activation mechanism of cytokine receptors upon ligand binding may
involve dissociation of the bound Jak.
In light of the structural information regarding the EpoR TMD and ICD ascertained by
these NMR studies, it is possible to begin connecting the various structural pieces of the receptor
(Figure 5.3). I have mentioned above that it is possible to connect the ligand-bound ECD crystal
structure (PDB ID:1CN4) with the EpoR TM dimer structure determined here by solution NMR
(Chapter 3). Chapter 4 describes the extension of structural studies past the TMD dimer to
include the Box 1 region that interacts with the Jak2 FERM domain. Using the dihedral angles
predicted from chemical shifts of backbone atoms in the ICD region, I extended the TM dimer
structure calculated in Chapter 3 to include ICD residues His249-Phe268. The conformation of
the Box 1 residues is governed by the cis conformations of the proline residues in this region.
No crystal structure exists for the Jak2 FERM domain, but through homology modeling
and computational studies, a model of the complete Jak2 structure has been proposed (166). The
FERM domain structure for the focal adhesion kinase (FAK) has been solved (167), it shows the
tri-lobed structure seen in other FERM domains (PDB ID:2AL6). One feature of this structure is
that a region of the FAK C-terminal to the FERM domain that corresponds to the SH3 binding
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site (RxxPxxP) binds in a groove between the F1 and F3 lobes of the FERM domain. This
peptide sequence has suspicious homology to the sequence immediately preceding and including
the Box 1 region of the EpoR (KIWPGIP). Hypothesizing that the Box 1 region of muEpoR218-268
also binds between the F1-F3 lobes of the Jak2 FERM domain, the Jak2 structure is positioned
such that the peptide aligns in this groove.
This exercise does not immediately suggest any keys for unlocking the mystery of
receptor activation. Rather, it hints that with the proper perspective, studying the receptor
piecewise and reassembling the pieces later may allow construction of a rational model of the
receptor. For instance, as mentioned in earlier sections, while the unliganded EpoR ECD is
incompatible with a TM dimer, the liganded ECD D2 domains connect easily with a TM dimer
(Figure 5.1). Combining the knowledge of Box 1’s role in Jak2 binding with the structural
knowledge of the FERM domain of other kinases provides clues about how to connect the two
proteins. Interestingly, when the Jak2 molecules are positioned on the EpoR TM dimer such that
the F1-F3 lobes of the FERM domain interact with the Box 1 region, there is no steric hindrance
between the Jak2 molecules on opposite monomers. It seems that with Jak2 positioned as such,
the FERM domain would just clear the membrane. The important Y1007/Y1008 residues near
the active site are positioned at the bottom of the Jak2 molecule, near the interface of the two
kinase molecules.
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ECD + Epo

TMD

ICD + Jak2
FERM

Jak2 Kinase

Figure 5.3 EpoR-Jak2 structure composite. The muEpoR218-268 structure based upon dihedral
angles is colored blue, with the interfacial residues of the dimer (S231, V235, S238, T242, A245,
and H249) are colored red. The Epo-bound EpoR ECD dimer (PDB ID:1CN4) is colored purple,
the WSXWS motif in magenta. Epo is light pink. The different domains of Jak2 (Jak2.pdb, (166))
are color-coded; the FERM domain is cyan, the SH2 domain is yellow, the pseudokinase domain
is grey, the kinase domain is green. Y1007/Y1008 are colored orange.
While the model presented above provides a compelling look into the possible structure
of the full-length EpoR with Jak2, it unfortunately does not give any indication of how small
changes in the EpoR TM structure upon activation would induce Jak2 activity. Clearly, these
studies are merely the beginning of the road with respect to determination of the full receptor
$-*

structure and ultimately, mechanism of activation. What is clear is that the TMD provides a
connection between the ECD and Jak2, and the activation signal is transduced through this
region. Building out from the TMD and successively studying larger and therefore more
biologically relevant receptor constructs, in an manner similar to cryo-electron microscopy
studies of the IL-6/IL-6R/gp130 complex (168), and the IL-6/IL-6R/gp130/Jak1 complex (169),
it should be possible to determine structures of EpoR in the inactive and active state using
solution NMR. The EpoR peptide/micelle system, as defined here, will allow the addition of the
FERM domain of Jak2 to the muEpoR218-268 sample in order to ascertain changes in Box 1
structure, as well as specific interactions between the two proteins. A range of experiment
possibilities is explored further in Chapter 7.
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Chapter 6-The S505N Mutation in the Thrombopoietin Receptor Drives Receptor
Dimerization
The thrombopoietin receptor (TpoR), along with its cognate ligand, thrombopoietin (Tpo)
governs megakaryocyte development and ultimately platelet production (170, 171). The
sequence of the receptor is related to the rest of the Group 1 cytokine receptors (EpoR, PrlR,
GHR), with two notable exceptions. First, the TpoR contains a duplicated ECD, resulting in an
ECD that contains two D1 domains and two D2 domains. Deletion of the combined membrane
distal D1-D2 domain results in constitutive receptor activity (157). Second, the TpoR contains a
five-residue insert directly C-terminal to the TMD, RWQFP (KWQFP in mice), that has been
shown to modulate receptor activity (158).
Much less is known about the structure of the TpoR than other Group 1 cytokine
receptors. A crystal structure of the ECD has not been solved. However, several point mutations
of the TpoR that cause disease in humans have been described; these have been helpful in
correlation of receptor structure with function. The S505N (172), W515K (35) and T487A (34)
mutations cause a gain of function of the TpoR, resulting in disease from thrombocythemia to
myelofibrosis. The positioning of these mutations is interesting. The S505N mutation resides in
the middle of the TMD, while the W515K and T487A mutations are in the intracellular and
extracellular juxtamembrane regions. The clustering of these mutations in and around the TMD
seems to underscore the importance of this region in receptor function. What is not completely
clear is how these mutations perturb receptor structure in order to cause activation.
TpoR Dimerization
Because the other Group 1 cytokine receptors have been shown to function in the active
state as dimers (45), it is reasonable to assume that the TpoR does as well. However, while
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experiments to determine preassociation of receptor chains in the absence of ligand has been
shown for the EpoR (73), GHR (52), and PrlR (16), the same experiments have not been
conducted for the TpoR. Association studies on the TMD sequence of the human TpoR using
cysteine mutagenesis and the TOXCAT expression reporter assay indicate that the wild type
TMD sequence of the huTpoR491-515 associates as a dimer (15). In this model, the interfacial
residues are G503, A506, L510, and L513. Interestingly, W515, when mutated to cysteine is also
able to crosslink receptors, despite being on the helix ‘outerface’ with respect to the heptad
interface defined above. There are two possible explanations for this result. The first is that the
W515C induces oligomers composed of more than just two monomers. The second is less
obvious. Alignments of the TMD-ICD of the EpoR and TpoR (Figure 1.4) indicate that the
R/KWQFP insert has no overlap with the rest of the EpoR sequence and is a true insert of five
residues (158). This would indicate that the five-residue insert may function as a unit, and the
lack of the QFP residues affects the structure of the TMD, and therefore, the results of the
Matthews et al. (15) series of experiments. For instance, typical #-helical backbone hydrogen
bonding proceeds in an i C=O to i+4 NH pattern. If we stipulate that the secondary structure is
helical through Pro518, then the NH groups of the missing Q516, F517 residues would be unable
to hydrogen bond with L512 and L513 carbonyls, disrupting the secondary structure of this
important region. This is especially relevant because activity studies on the full-length receptor
with the RWQFP insert deleted is constitutively active (158).
In order to determine the contribution of the TMD and the insert region to the function of
the TpoR, we decided probe the structural characteristics of the entire human TpoR TMD
including the insert region using solution NMR. The construct sequence chosen (huTpoR481-520)
stretches from the end of the "-sheet rich D2 domain to two residues after Pro518, so it should be
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possible to assess the native structure and function of the complex. Because there are several
clinically important disease-causing mutations in and around the TMD of the TpoR (T487A,
S505N, W515K), peptides corresponding to these mutations can be studied alongside the WT
peptide in order to determine the biological relevance of the results. We find that the WT peptide
contains a kink in the TM helix such that there are two separate helices, an observation that
corresponds to previous NMR studies of this peptide (147). We also find that the S505N
mutation increases the oligomerization state of the TpoR481-520 peptide. Furthermore, there is also
a change in secondary structure of the peptide associated with this active state, a straightening of
the helix through the kinked region observed in the WT peptide. Together, these results indicate
that the S505N mutation functions by changing the oligomerization state of the TpoR TMD.
Furthermore, the change in secondary structure may mimic the change in TMD structure induced
by the binding of the natural ligand, thrombopoietin.
Structural Data on the TpoR WT and S505N Peptides
The huTpoR481-520 WT and S505N peptides were expressed as His-MBP fusion proteins
in E. coli BL21(DE3) cells and purified as previously described (173). Reconstitution of the
peptides into DPC micelles as was performed for the EpoR TM peptides revealed that the
huTpoR481-520 S505N peptide yielded poor quality spectra (data not shown). Repeated
purification and different buffer conditions (changing pH, buffer and salt concentrations) did not
improve the spectrum. However, reconstitution of each peptide in d25-sodium dodecyl sulfate
(SDS) micelles yielded good quality spectra (Figure 6.1) that were used for 3D backbone studies.
Interestingly, despite the sequence differing by a single amino acid, the two spectra were very
different, an indication that the two conformations are very different.
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Figure 6.1 Comparison between 1H-15N HSQC from huTpoR481-520 WT and S505N
demonstrate large chemical shift changes. huTpoR481-520 WT (black) and S505N (red)
reconstituted into SDS detergent micelles yielded high quality HSQC spectra. Samples were 1
mM peptide in 10 mM sodium phosphate, pH 4.7, 85x CMC d25-SDS, 10% D2O (v:v). Spectra
were collected at on a 700 MHz spectrometer at 320 K, 32 scans each.

Backbone chemical shift assignments for the WT and the S505N peptides (Figure 6.2 A,
B) reveal secondary structure changes from WT to S505N peptides reconstituted into SDS
micelles. Carbonyl chemical shift changes in the N-terminus of the TM helix occur between WT
and S505N, particularly at residue I492. Changes in #-helical geometry for the TM helix would
be expected to result in paired shift of the carbonyl and its i+4 hydrogen-bonding partner’s amide
proton. This is seen for the I492 carbonyl-T496 amide pair, and the downfield shift of the I492
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carbonyl is indicative of greater #-helical geometry for this region of the S505N peptide. The
conclusion from these observations is that there seems to be an increase in #-helical character of
the TMD N-terminus in the S505N peptide in the region surrounding I492-T496.

A.

T496
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B.

I492

Figure 6.2 Backbone chemical shift changes between WT and S505N peptides suggest
secondary structure changes from WT to S505N. A) Backbone NH chemical shift changes from
huTpoR481-520 WT and S505N demonstrate large changes in I492 and T496. B) Carbonyl
chemical shift changes indicate that the carbonyl of I492 shifts downfield in the S505N peptide.
The NH bond vector is particularly sensitive to changes is secondary structure and local
environment. Flexibility of the peptide backbone can be assessed by probing the 1H-15N
heteronuclear NOE relaxation NMR experiments (97). The heteronuclear NOE values of
huTpoR481-520 WT and S505N in SDS micelles are presented in Figure 6.3. One of the most rigid
residues in the WT peptide is Thr496, previously identified as a residue that has a large NH
chemical shift change from WT to S505N. In the S505N peptide, the rigidity of Thr496
decreases, while Thr487 becomes more rigid. The changes in rigidity of Thr487 and Thr496
seem to be coupled to the structural change indicated by the chemical shift deviations seen in the
Ile492 carbonyl and the Thr496 NH. Together, these changes in flexibility are consistent with a
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change in secondary structure of Ile492-Thr96 to #-helix. Why Thr487 is perturbed by a
mutation at S505N is not clear. A Thr487 mutation to alanine has previously been identified as a
clinically important TpoR activating mutant in humans (34). Perhaps a shift in the conformation
of Thr487 is critical for achieving the active state. Interestingly, in a continuous helix, Thr487
would be on the same face as S505N. This would place it in the interface of a helix dimer that is
mediated by the S505N mutation, potentially explaining the increase in rigidity seen in the
S505N peptide.

T496

510

490

500

T487

Figure 6.3 Backbone flexibility of the WT and S505N huTpoR481-520 peptides in SDS micelles.
1
H-15N Heteronuclear HSQC experiments conducted on the WT and S505N peptides indicate a
change in flexibility of two threonine residues at the N-terminus of the peptide. Interscan delay =
3s. blue=WT, red=S505N
The structural information encoded in the chemical shift measurements allows prediction
of dihedral angles using the program DANGLE (105). The dihedral angles were used to create
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structural models using CNS (102, 103). A single round of structure calculation (representing
structures that are the result of dihedral angle input and a single round of minimization) produced
the structures in Figure 6.4. The WT model (in green) demonstrates a kink in the helix around
T496, which is consistent with a structural model based upon solid-state NMR measurements of
the WT peptide in lipid (147). Conversely, the S505N model (in cyan) shows a continuous helix
in this region of T496, consistent with the downfield shift of the carbonyl of I492. Together these
data demonstrate that the mutation at position 505, which is more than 2 helix turns away from
T496, induces a dramatic structural change in the TMD.

Figure 6.4 Structural models of the WT and S505N huTpoR481-520 peptides in SDS micelles.
Dihedral angles computed from backbone chemical shift measurements were used to create
stereo structural models of the WT and S505N peptides. The sidechains of T487, W491, T496,
S/N505, and W515 are visible. Green=WT, Cyan=S505N.

That the 1H-15N-HSQC for the TpoR WT and S505N peptides demonstrate such a
dramatic structural change upon the mutation of a single amino acid is unexpected. The 1H-15NHSQC of muEpoR218-268 peptides with the L223C mutation (Chapter 4) demonstrates mostly
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local changes in the peptide structure, along with a few residues distal to the site (His249,
Leu253) associated with a shift to the activating state. One potential model that explains how
such a large change in structure occurs upon the mutation of a single amino acid is TMD
oligomerization. In model TMD peptides, polar residues such as asparagine can drive helix
association (174). Changes in the oligomerization status of the huTpoR481-520 peptide in SDS
detergent micelles upon mutation of serine 505 to asparagine can be assessed by relaxation NMR
techniques (97). T1 (spin-lattice) relaxation and T2 (spin-spin) relaxation of the amide NH are
sensitive to the rate of molecular tumbling and can be easily assessed with a series of 1H-15NHSQC based experiments. Histograms of these measurements are presented in Figure 6.5 and
6.6, demonstrating that while there is no difference in the T1 values for the WT peptide, the T2
values for the S505N peptide are roughly half that of the WT peptide. Faster relaxation for the
S505N peptide is consistent with a larger complex, suggesting TM oligomerization.
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Figure 6.5 Determination of T1 values for the WT and S505N huTpoR481-520 peptides in SDS
micelles. T1 relaxation values for each NH in the WT and the S505N samples were determined
using solution NMR. Pro518 has been omitted from the histogram. Interscan delay = 3s.
blue=WT, red=S505N.
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Figure 6.6 Determination of T2 values for the WT and S505N huTpoR481-520 peptides in SDS
micelles. T2 relaxation values for each NH in the WT and the S505N samples were determined
using solution NMR. Pro518 has been omitted from the histogram. Interscan delay = 3s.
blue=WT, red=S505N.

The correlation time (!c) of each residue in the complex can be calculated using the formula (97):
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Typically, these values are averaged over the amino acids that demonstrate a heteronuclear NOE
value greater than 0.6 (relatively rigid) to measure the correlation time of the molecule (128).
The !c calculations were performed for the WT and S505N peptides solubilized in SDS micelles
and the results are presented in the histogram below (Figure 6.7). Because the calculation of !c is
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dependent on the ratio of T1/T2, as expected the correlation time of S505N is roughly twice the
rate of the WT peptide. This is another indication that the oligomerization state has changed from
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the WT to S505N peptides.

Figure 6.7 Calculated values of !c values for the WT and S505N huTpoR481-520 peptides in
SDS micelles. Correlation time of each NH in the WT and the S505N samples were determined
from the T1/T2 relaxation values and the formula in the text. Pro518 has been omitted from the
histogram. blue=WT, red=S505N.

Conclusions
The peak shifts in the 1H-15N-HSQC between WT and S505N peptides suggests that the
single amino acid difference causes a dramatic change in the structure of the TM peptide. The
relaxation NMR data suggests that this dramatic structural change is related to a change in
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oligomerization state of the peptide. The huTpoR481-520 TM peptide monomer is ~4.7 kDa, and
the average SDS micelle is ~17 kDa (288.3 g/mol x aggregation number 62), for a total
peptide:detergent complex size of ~26.4 kDa. A study of the BNIP3 TM peptide dimer prepared
in isotropic DHPC/DMPC bicelles with a complex size of ~50 kDa measured a correlation time
of ~18 ns (128). The S505N correlation time is ~8 ns, about half the BNIP3 !c, which fits well
with the molecular weight of a huTpoR481-520 peptide dimer in an SDS micelle. Interestingly,
other data in our lab suggest that S505N induces TM dimerization. AUC experiments in DPC on
peptides corresponding to the TMD of the human TpoR demonstrate that the WT sequence is
monomeric and the S505N peptide forms TM dimers (175). Similar results were seen using
deuterium NMR experiments with the same peptides reconstituted in DMPC bilayers (175).
Interface
If the S505N TM peptide forms a dimer in SDS micelles, then what is the peptide dimer
interface? While there is not enough data to determine precisely what the interface of such a
dimer would be, it is reasonable to hypothesize that the Asn505 residue would be in a helix
dimer interface. Several studies on Asn-containing model TM peptides (136, 138, 139) and Asn
mutagenesis of actual TMD peptides (64, 176) indicate that asparagine can mediate
oligomerization of TM helices. If Asn505 is in the interface of the TM dimer, then two interfaces
are possible, one where Asn505 is in the “a” position, one where it is in the “d”position (labeled
“1” and “2” on Figure 6.8 below). If interface “1” is the actual interface, then this would place
Thr487 and Trp515 in the interface of the active dimer. This is an interesting observation, as
mutation of each of those residues causes disease associated with receptor hyperactivity in
humans (34, 35). Interface “2” represents a model supported by TOXCAT assay data (15).
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Figure 6.8 Helical wheel diagram of the huTpoR481-520 peptide TMD sequence. Left-handed
coiled coil diagram for the WT huTpoR481-520 peptide sequence. Potential active interfaces “1”
and “2” are labeled. Blue=TM helix start, red=TM helix end, gray=N-terminal helical region.

The results of these experiments suggest that the clinically relevant S505N mutation
induces receptor activation by driving dimerization of the TMD. This conclusion is supported by
the change in correlation time of the peptide containing the S505N mutation, which suggests a
change in oligomerization state. What is less clear is how the change in oligomerization state is
associated with structural changes in the N-terminus of the receptor TMD. Using a combination
of solid and solution NMR, Kim et al., (147) demonstrate that the WT TpoR TMD is broken into
two helices, separated by a kink around I492-T496. This helical break is reproduced by our
solution NMR data as well. It is clear from the downfield shift in carbonyl resonance of I492 and
the amide chemical shift of T496 that in the presence of the S505N mutation, this region
becomes more helical. The reason behind this structural change is unclear. One possibility is that
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the straightening of the helix could occur to accommodate formation of interhelical interactions
between N-terminal residues of opposite receptor monomers, a “zippering-up” of this region.
Assuming the Kim et al. (147) model is correct, and the N-terminal helix resides along
the membrane surface, helix straightening would serve to lift it off the membrane. This could lift
the entire EC-JM region off of the membrane. Interestingly, such a model has some support.
Weidemann et al. (177) have hypothesized that the IL-4 receptor WSXWS motif functions as a
molecular switch, modulating receptor activity. Using free energy perturbation calculations, they
demonstrate that the tryptophan residues of the WSXWS motif could reside in two
conformations. In the ‘off,’ or inactive state, the Trp residues partition into the membrane,
tethering the ECD to the cell membrane. In the ‘on,’ or active state, the ECD is lifted off the
membrane and the Trp residues rotate inward to interact in the Trp-Arg zipper motif seen in the
various crystal and NMR structures of the ECD D2 domain (4, 10).
More recent research gives support to a role for WSXWS as a molecular switch. NMR
studies on the PrlR ECD in the absence and presence of Prl demonstrate a change in the
conformation of the tryptophan residues in the WSXWS motif; in the ligand-bound state, the Trp
sidechains form the Trp-Arg zipper (178). However, in the unbound state, the two Trp sidechains
form a T-stack conformation, with the edge of one Trp ring stacking on the face of the other Trp.
The consequence of this conformational change is a structural rearrangement of the D2 domain
"-sheets. These changes do not mirror the structural changes hypothesized by the free energy
perturbation studies of Weidemann et al., (177), since lipid was clearly unavailable for Trp
sidechain partitioning. Given that mutational studies have clearly implicated the WSXWS motif
in receptor activity (12), and now structural studies have demonstrated a conformational
difference of the WSXWS motif between the ligand bound and free ECD structures, it seems
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reasonable that this motif plays a greater role in receptor function than originally thought.
Clearly more research on larger receptor constructs in a biologically relevant system (lipid) is
necessary to probe the structure and function of the hematopoietin receptor family. However, the
experiments described here are the necessary precursor to these more difficult studies and
establish the structural changes induced by the S505N mutation that are associated with receptor
activation.
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Chapter 7-Conclusions and Future Directions
The data contained herein describe the structure of cytokine receptor TMD dimers and
provide insights into the mechanism(s) of how structural changes induced by ligand binding may
be transmitted through the TMD to the ICD. However, the broader picture that emerges from the
study of these peptides includes three important observations. First, the structures of cytokine
receptor TMD dimers can be elucidated by solution NMR. While the ability to derive structural
information from TMD dimers has been well established (81, 125, 179), none of the cytokine
receptor TMD structures have been reported. The second observation from these studies is that
mutations in the TM or JM regions can be added to the WT peptides to assess structural changes
either locally or distally. Assessment of structural changes upon the addition of the S505N
mutation in the background of the huTpoR TMD peptide demonstrates that not only can
differences in oligomerization state be examined, but also the structural changes associated with
oligomerization. The third point is the observation that the sequence of the TMD encodes
secondary structure information (#-helix) that directs the proper folding and assembly of this
region. To date, solution NMR studies on single TM receptors have focused on separate regions
of the receptor such as the D2 domain (4) or the TMD dimer (122, 179). These studies are the
necessary first steps for investigation of relationships between receptor structure and function.
The muEpoR220-248 peptide spontaneously folds into an #-helix and dimerizes in DPC micelles
(Chapter 3). When additional residues corresponding to the switch and Box 1 regions are added
(muEpoR218-268), the secondary structure and TMD dimer interactions are preserved (Chapter 4).
The addition of these regions provides context for assessing the role of activating mutations with
respect to receptor structural changes.
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Finally, the recapitulation of interactions that occur in vivo can be made. While solution
NMR has long been used to assess structural changes of soluble interacting proteins, it has not
been widely used for TMD-containing proteins. The TMD of gp55-P interacts with the TMD of
muEpoR, thereby activating the receptor. This work demonstrates that those TMD interactions
can be recreated in a membrane mimetic system and associated structural perturbations can be
assessed using solution NMR. Together, these experimental observations set the stage for
collecting more biologically relevant data to elucidate the relationship between the structure and
function of cytokine receptors.
EpoR
Several potential avenues for extending the studies of the EpoR are available. Two
subsets of experiments in particular can be considered based on experiments already performed.
These fall into two separate categories, the addition of secondary interacting molecules or
proteins (e.g. gp55-P) or extension of the sequence to study different regions of the receptor. For
the first subset of experiments, it would be helpful to characterize the molecular interactions of
the EpoR and gp55-P TMDs. This would not just define the interface between the EpoR and
gp55-P, but also help define what changes in the EpoR TMD are associated with activation. An
additional experiment that would be helpful here is to study the human EpoR TMD sequence
with the L239S mutation that allows gp55-P activation of the receptor with the human sequence
(39).
Interestingly, there is a second, albeit synthetic, TMD-containing protein that has been
demonstrated to activate the EpoR through TMD interactions (180). This peptide has no
sequence homology to gp55-P. It would be instructive to perform the same structural studies
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with the muEpoR218-268 peptide in DPC micelles to assess whether the same structural changes
are seen as with the active constructs studied here (L223C, +gp55-P).
Extension of the sequence construct from the core TMD region that we have studied here
could help shed light on regions of the receptor that to date have not been studied. For instance,
the JM regions of the receptor are areas of structural transition between the ECD "-sheet rich
region and the #-helical TMD. In TpoR, mutations in these regions cause constitutive receptor
activity and disease (34, 35). However, the changes in structure of these regions associated with
the active state are unknown. By adding the sequence of the ECD D2 domain to the TMDcontaining peptide, the structure of the JM region between the WSXWS motif and the Nterminus of the TMD in a more native conformation can be studied.
Furthermore, two modalities in addition to the JM cysteine mutations (74) can be used to
simulate the active state. The R129C mutation causes EpoR hyperactivity by inducing receptor
dimer crosslinking (32). This mutation can be introduced and NMR can ascertain structural
changes from the WT peptide. A second method of activation is to add an activating peptide.
Naranda et al. (181) have determined that a sequence corresponding to residues 194-216 of the
EpoR activates the full length EpoR. This peptide could be added to WT D2-TM peptides to
simulate an active state, and again structural changes caused by the addition of the activating
peptide can be determined through NMR experiments. The EpoR 194-216 peptide has been
shown to bind to its identical sequence on the full receptor (181). Interestingly, the peptide
includes an arginine residue (R171) demonstrated by X-ray crystallography to interact with a
tryptophan residue (W212) of the WSXWS motif (8), suggesting this region has a role in
receptor activation. Moreover, given the concentration of activating mutations in the EC-JM
region in both the EpoR and TpoR, perhaps the WSXWS motif and the EC-JM region work in
$%*

concert to regulate receptor activity. The structural importance of this region is an area of active
study, as a recent study of PrlR demonstrated that the WSXWS motif acts as a molecular switch
(178). Clearly, study of this region of the receptor is critically important for determining how
changes in ECD orientation upon ligand binding are transmitted to the TMD, and would
ultimately shed light on an activation mechanism of these receptors.
Extension of the TMD-containing construct further into the ICD would be helpful as
well. We have cloned and expressed a construct (muEpoR218-392) that extends the TM+Box 1
construct through the Box 2 region and includes the first tyrosine phosphorylated by Jak2 upon
Epo binding (Y343). We were able to purify this peptide, reconstitute it into DPC micelles and
perform NMR studies. Unfortunately, the spectrum exhibited severe overlap, either because of
chemical shift broadening due to slow molecular tumbling (approximate complex size is ~55
kDa) or conformational heterogeneity (data not shown). However, use of technological advances
for study of larger complexes can be helpful here. Deuteration of peptide sidechains, combined
with TROSY NMR pulse sequences (119), can narrow linewidths of resonances in larger
molecular weight complexes and make them amenable to study by solution NMR methods.
Once the structural conformations of the WT muEpoR218-268 and muEpoR218-392
complexes have been determined, the FERM domain from Jak2, expressed separately, can be
added to each peptide complex. This would provide information on the binding site of the FERM
domain on the EpoR and how that interaction changes the local and the global structure of the
complex. Difficulties due to the size of this complex may arise, but can be overcome with the
TROSY method mentioned above (119). Structural details of near-megadalton protein
complexes have successfully been studied in this manner (182).
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TpoR
The avenues for continuing the research on the TpoR TMD are similar to the EpoR
project. Given that the data described here clearly implicate the S505N mutation in receptor
TMD association, it seems natural to continue experiments to determine the receptor interface.
This would be more than merely an academic exercise. The rotational orientation of the murine
TpoR TMD is linked to differential signaling of the receptor (183). The interface represented by
the active S505N TM dimer induces proliferation to near WT-like levels, activating the
Jak2/STATs, the MAPK and PI3K pathways, but not Tyk2. Further structural study of these
interfaces will elucidate how the changes in TMD rotational orientation is coupled to changes in
ICD orientation, and thus allows differential activation of intracellular pathways to effect
specific physiological responses.
Another interesting question to be answered involves the role of the K/RWQFP insert in
TpoR. This insert modulates the activity of the receptor in a sequence specific fashion (158).
However, the actual mechanism of function is unknown. Mutation of Trp515 to lysine, leucine
(35) or alanine (158) results in a constitutively active receptor, suggesting a role for Trp514 of
this motif in the preventing activation. Even more mysterious is how activation by native ligand
or S505N mutation is able to overcome the inhibition provided by this tryptophan. By studying
TMD-containing peptides in the same manner as described here for the EpoR TM constructs, it is
possible to determine how Trp515 and various mutants act in these cases. In a similar fashion,
the structure of the active T487A mutant can be studied as well. It would be interesting to see if
these mutants share a common structure and therefore method of activation, or if different
structures lead to the same result.
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Finally, in the same vein as the EpoR, longer TpoR TMD-containing constructs can be
expressed that include the Box 1 region in order to determine the molecular contacts between the
TpoR ICD and the FERM domain of Jak2. This experiment has particular importance, as the
TpoR is known to use two different kinases, Jak2 and Tyk2 (184). Such experiments could help
determine the mechanism of kinase specificity in cytokine receptors.
Of course, while the potential experiments described here primarily utilize solution
NMR, other approaches to assess structure should not be ruled out. X-ray crystallography may be
useful in determining the structure of the ICD region if expressed by itself, or in complex with
the FERM domain of Jak2. Solid-state NMR experiments are generally unable to obtain the
resolution of solution NMR experiments, but have the advantage of being able to examine
peptide structure in a native lipid environment, which may be desirable.
These structural characterizations or TMD containing peptides all lead to increasing the
understanding of how these receptors function. Once Epo is bound to the ECD, the TMD shifts
to the active conformation, and the ICD structure is reorganized to allow activation of Jak2. But
how does this occur? If Jak2 disengages from Box 1 when the EpoR is activated, what structural
changes would cause this to happen? What methods of regulation would exist to keep a free,
soluble Jak2 from phosphorylating without limits? Much still remains to be discovered regarding
the function of these receptors. It will be even longer until therapeutics can be developed based
on the structural insights gleaned from these studies. However, the studies described here begin
to define the role of the TMD in these receptors both structurally and functionally and represent
the necessary first steps for understanding how these proteins function.
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Appendix
Chemical Shift Tables
A.1 muEpoR220-248 chemical shifts in 10 mM sodium phosphate, pH 7.0, 200 mM d38-DPC,
10% D2O (v:v)

220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248

Seq
S
N
A
S
D
L
D
P
L
I
L
T
L
S
L
I
L
V
L
I
S
L
L
L
T
V
L
A
L
L
S

C=O

177.651
174.347
176
176.053
178.879
178.314
179.21
177.787
175.918
178.261
175.117
178.507
177.269
179.929
177.227
178.717
177.451
176.856
178.073
178.503
178.448
176.177
177.602
179.241
179.747
178.162
176.206

Ca

Cb

Ha

N

53.163
53.586
59.054
54.648
54.522
53.491
65.405
58.395
64.227
58.613
68.434
58.249
63.708
58.205
65.608
58.436
67.332
58.895
65.476
63.753
58.297
58.531
58.18
68.33
67.362
58.233
54.891
56.602
55.018
61.068

39.314
18.923
63.661
41.39
42.967
42.3
32.287
41.467
36.932
41.963
68.083
41.798
62.891
41.605
37.282
41.393
31.212
41.688
37.565
62.688
41.932
41.729
41.77
67.747
31.25
41.674
18.6
42.762
42.795
65.056

4.793
4.202
4.317
4.623
4.297
4.231
4.117
3.675
3.978
3.699
3.942
3.996
3.942
3.554
3.974
3.468
3.943
3.584
4.019
3.989
3.924
3.96
3.727
3.503
3.942
4.045
4.238
4.4
4.187

112.08236
121.31871
120.5382
123.5524
121.08517
118.829
121.42733
115.23447
119.39
114.49025
121.10517
118.28963
119.15964
120.9879
119.94409
117.21661
116.59416
124.19183
119.42783
116.863
116.1027
120.07525
117.81175
120.20555
116.33357
117.61337
119.84088

A.2 muEpoR220-248 chemical shifts in 90% trifluoroethanol, 10% deuterated chloroform (v:v)
C
N219
A220
S221
D222

Ca
172.185
175.321
172.61

Cb
50.546
51.914
57.875
51.784

H
36.334
15.324
61.313
35.041

$(-

N
8.658
8.075
8.393
8.233

116.43
122.801
111.785
118.254

L223
D224
P225
L226
I227
L228
T229
L230
S231
L232
I233
L234
V235
L236
I237
S238
L239
L240
L241
T242
V243
L244
A245
L246
L247
S248

174.829
176.219
175.574
177.117
176.453
173.234
176.541
172.499
175.147
178.532
175.641
177.528
175.513
174.383
176.21
176.991
177.438
173.249
175.725
178.038
178.136
177.699
176.107

53.174
53.117
63.836
56.137
62.278
56.348
65.532
56.1
60.367
55.874
63.018
56.172
65.15
56.512
62.904
60.686
56.339
56.392
55.989
65.2
65.321
56.134
53.163
55.788
54.243
56.125

40.241
33.927
28.797
39.406
35.276
39.59
67.009
39.476
39.501
35.41
39.139
29.186
39.255
35.423
39.54
39.376
39.386
66.698
29.247
39.339
14.965
39.854
40.153
61.926

8.049
8.146

119.041
118.323

7.761
8.036
8.711
8.199
8.826
8.491
8.21
8.453
8.512
8.469
8.69
9.298
8.477
8.853
8.722
9.121
8.254
8.78
8.78
8.594
8.72
8.873
8.199

119.359
118.958
121.774
114.9
120.732
113.326
122.352
119.769
118.811
122.012
121.5
118.944
115.886
126.305
121.366
117.1
116.163
122.551
118.664
123.071
119.949
118.144
113.901

A.3 Wild type muEpoR218-268 chemical shifts in 10 mM sodium phosphate, pH 7.0, 200 mM
d38-DPC, 10% D2O (v:v)
Wild Type

218
219
220
221
222
223
224
225
226
227
228
229
230

S
N
A
L
T
A
S
D
L
D
P
L
I
L
T
L

C

Ca

Cb

H

174.64904
177.39068
176.76146
174.49302
177.8703
174.27282
175.82701
176.07547

53.51418
53.00189
55.65966
61.00128
53.55676
59.26771
54.8776
54.58111
54.42775

39.50878
19.75242
42.75389
70.21197
19.2455
63.72775
41.52073
43.08118
43.03436

178.29115
179.25282
177.80552
175.95305
178.29815

58.58417
64.25483
58.84924
68.0918
58.51818

41.52057
36.98435
41.93387
41.88574

$($

N

8.36448
8.27975
8.12354
8.49114
7.97884
8.08274
7.72845
8.189

123.36188
119.51994
112.39972
124.62308
112.44594
120.65205
120.09381
123.34001

7.84571
8.21059
7.94914
8.31024

119.01423
121.60099
115.36954
119.41597

231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268

S
L
I
L
V
L
I
S
L
L
L
T
V
L
A
L
L
S
H
R
R
T
L
Q
Q
K
I
W
P
G
I
P
S
P
E
S
E
F

175.15035
178.55808
177.30515
179.97502
177.25092
178.7409
177.48313
176.86862
178.08519
178.57424
178.36977
176.30861
177.63102
179.37623
179.82444
178.89799
179.52534
175.31898

63.53921
58.30516
65.517
58.49818
67.10518
58.82468
65.28394
63.63482
58.60595
58.8893
58.43049
68.21235
67.39633
58.57203
55.64047
58.23828
57.5618
60.95305
57.14116

178.09474
176.35464
178.3113
177.31
176.71167
176.75494
174.73794

59.20649
65.4327
57.51019
59.46324
57.34407
57.0598
62.52286
55.49808
63.41782
45.17598
58.64655
63.24791
56.18249
63.52479
56.99261
58.32796
56.85047
58.83643

177.92646
173.84061
176.46355
177.03438
176.45209
174.06548
175.0503

62.76026
41.67067
37.35079
41.49307
31.29531
41.67313
37.73762
62.63005
41.99451
41.88437
41.71903
31.215
41.53489
18.53608
42.27027
42.15666
63.40101
30.74674
29.44758
68.5985
42.18068
28.80213
28.98848
33.02405
38.75947
29.03703
32.10553
38.58278
32.12214
63.54117
32.0578
30.1038
63.97491
30.60347
40.52133

8.17696
7.91081
8.04518
8.24393
8.31149
8.34538
8.66729
8.14779
8.43321
8.2851
8.56275
7.85895
8.23644
8.31669
8.56764
8.36416
8.41682
8.09369
7.91674
7.72036

114.61253
121.13175
118.3965
119.21893
121.11908
119.97857
117.3096
116.71553
124.34448
119.48266
117.0672
116.02906
120.37464
118.70518
122.22491
118.32277
117.03651
113.59026
119.27719
120.13266

7.78609
7.91977
8.46463
7.76434
7.60337
7.55505
7.98595

114.32036
120.51861
118.15121
115.92335
116.54817
116.74118
118.84649

8.21028
7.80287

107.78397
121.40432

8.29015

117.18823

8.41722
8.00553
8.19624
7.5768

119.77598
115.44215
122.80193
124.65485

A.4 L223C muEpoR218-268 chemical shifts in 10 mM Sodium phosphate, pH 7.0, 200 mM d38DPC, 10% D2O (v:v)
L223C
C

218

S
N
A
L

176.821

Ca

Cb

55.732

H

42.386

$(%

N

8.277

119.142

219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267

T
A
S
D
C
D
P
L
I
L
T
L
S
L
I
L
V
L
I
S
L
L
L
T
V
L
A
L
L
S
H
R
R
T
L
Q
Q
K
I
W
P
G
I
P
S
P
E
S
E

174.384
177.838
174.237
175.7
173.546
178.82
178.272
179.136
177.829
175.934
178.294
175.132
178.552
177.328
179.954
177.227
178.728
177.474
176.87
178.08
178.587
178.376
176.326
177.636
179.388
179.798
178.843
179.33
175.255
176.05
178.058
176.33
178.313
177.311
176.694
176.715
174.714
177.904
173.843
176.45
177.024
176.451
174.063
175.054

61.141
53.08433
59.39933
54.51467
58.552
53.121
65.383
58.40767
64.13933
58.59967
68.23767
58.097
63.894
58.244
65.668
58.45467
67.44333
58.86033
65.42567
63.805
58.241
58.536
58.2865
67.791
67.576
58.47233
55.603
58.041
57.41333
61.134
57.081
58.986
65.131
57.5965
59.517
57.446
56.912
62.66167
55.546
63.788
45.1335
58.672
63.0305
56.293
63.7025
56.96433
58.30467
56.802

70.1395
19.211
63.88067
41.23033
28.66067
42.399
32.35
41.38433
36.904
41.95367
41.77667
62.99533
41.555
37.32067
41.2975
31.158
41.65033
37.42867
62.571
41.9075
41.678
41.7
67.818
31.167
41.56333
18.38233
42.091
42.0985
63.771
30.734
29.38193
68.77733
42.023
28.741
28.93833
32.663
38.799
28.988
32.013
38.576
32.0975
63.728
32.017
29.99633
64.121
30.54633

$(&

7.961
8.38925
8.05525
8.14813
7.854
8.55413

111.8895
124.86525
113.06175
120.69475
117.7355
125.88562

8.584
7.77787
8.1305
7.91743
8.34033
8.17475
7.914
8.05513
8.25713
8.3085
8.34237
8.68112
8.15888
8.44688
8.299
8.57817
7.867
8.2554
8.32175
8.57387
8.36925
8.38917
8.06267
7.973
7.792

121.447
118.83925
121.71637
115.20071
119.38467
114.58988
121.06043
118.35988
119.238
121.05838
120.03037
117.27037
116.71625
124.30113
119.4355
117.08717
116.12637
120.3908
118.6065
122.08013
118.25538
117.09367
113.39817
119.339
120.218

7.78555
7.91443
8.46525
7.78586
7.61057
7.54887
7.99063

114.31694
120.52314
118.20675
115.93529
116.58271
116.6725
118.80862

8.208
7.803

107.74725
121.37267
117.15088

8.29262
8.42513
8.00975
8.201

119.76538
115.43213
122.782

268

F

58.927

40.463

7.579

124.65387

Structure Parameter Table
A.5 Murine EpoR TM dimer structure parameters
Experimental Restraints per Monomer
# of NOE restraints
Intraresidue
Inter-residue
sequential
medium-range
long-range
unambiguous intermonomer
# of Hydrogen Bond Restraints
# of Torsion Angle Restraints
Backbone !
Backbone "

241
105
92
7
66
15
52
26
26

Structure Statistics
Restraint Violations
Distance (>0.5 Å)
2.53
Distance (>0.3 Å)
2.42
Dihedrals (>5°)
13
Deviation from idealized geometry
Bonds (Å)
0.0085 ±0.0005
Angles (deg)
1.141 ±0.096
Impropers (deg)
4.23 ±0.569
Deviation from experimental restraints
NOEs
Dihedrals (deg)

24
7.39
RMSD

Backbone atoms
All Heavy Atoms
%
%
%
%

2.05
2.64

Ramachandran Analysis
Most Favored
Allowed
Generously Allowed
Disallowed

$('

72.1
24.8
2.34
0.72

